

# Role of ADAMTS (A Disintegrin and Metalloproteinase With Thrombospondin Motifs)-5 in Aortic Dilatation and Extracellular Matrix Remodeling

Marika Fava, Javier Barallobre-Barreiro, Ursula Mayr, Ruifang Lu, Athanasios Didangelos, Ferheen Baig, Marc Lynch, Norman Catibog, Abhishek Joshi, Temo Barwari, Xiaoke Yin, Marjan Jahangiri, Manuel Mayr

**Objective**—Thoracic aortic aneurysm (TAA), a degenerative disease of the aortic wall, is accompanied by changes in the structure and composition of the aortic ECM (extracellular matrix). The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of proteases has recently been implicated in TAA formation. This study aimed to investigate the contribution of ADAMTS-5 to TAA development.

**Approach and Results**—A model of aortic dilatation by AngII (angiotensin II) infusion was adopted in mice lacking the catalytic domain of ADAMTS-5 (Adamts5<sup>Δcat</sup>). Adamts5<sup>Δcat</sup> mice showed an attenuated rise in blood pressure while displaying increased dilatation of the ascending aorta (AsAo). Interestingly, a comparison of the aortic ECM from AngII-treated wild-type and Adamts5<sup>Δcat</sup> mice revealed versican as the most upregulated ECM protein in Adamts5<sup>Δcat</sup> mice. This was accompanied by a marked reduction of ADAMTS-specific versican cleavage products (versikine) and a decrease of LRP1 (low-density lipoprotein-related protein 1). Silencing *LRP1* expression in human aortic smooth muscle cells reduced the expression of ADAMTS5, attenuated the generation of versikine, but increased soluble ADAMTS-1. A similar increase in ADAMTS-1 was observed in aortas of AngII-treated Adamts5<sup>Δcat</sup> mice but was not sufficient to maintain versican processing and prevent aortic dilatation.

**Conclusions**—Our results support the emerging role of ADAMTS proteases in TAA. ADAMTS-5 rather than ADAMTS-1 is the key protease for versican regulation in murine aortas. Further studies are needed to define the ECM substrates of the different ADAMTS proteases and their contribution to TAA formation. (*Arterioscler Thromb Vasc Biol.* 2018;38:00-00. DOI: 10.1161/ATVBAHA.117.310562.)

**Key Words:** aneurysm ■ blood pressure ■ extracellular matrix ■ mice ■ thrombospondin

ECM (extracellular matrix) degradation and remodeling is a hallmark of aortic aneurysm formation. The precise mechanisms behind the degradation of ECM components and subsequent dissection of the vessel wall are not completely elucidated. Histologically, diseased aortas present with variable degrees of ECM degeneration within the aortic medial layer, including cystic medial degeneration, elastic fiber fragmentation, and myxomatous degeneration. At the molecular level, aortic degeneration has been associated with vascular smooth muscle cell (SMC) apoptosis<sup>1</sup> and inflammation.<sup>2</sup> Factors that contribute to aortic wall degeneration both in humans and in animal models include AngII (angiotensin II),<sup>3</sup> TGF- $\beta$  transforming growth factor- $\beta$ ,<sup>4</sup> and MMPs (matrix metalloproteinases).<sup>5</sup> The role of MMPs in the alteration of aortic ECM architecture has been extensively studied in the

context of aortic aneurysm development.<sup>5,6</sup> More recently, a family of metalloproteases known as ADAMTSs (a disintegrin and metalloprotease with thrombospondin motifs) has been explored in vascular ECM turnover. In particular, ADAMTS-1, -4, and -5 activities have been implicated in thoracic aortic aneurysm (TAA) formation.<sup>3,7,8</sup>

ADAMTS-1, -4, and -5 are the main enzymes responsible for large aggregating proteoglycan cleavage.<sup>9,10</sup> We have previously demonstrated that ADAMTS-5 is reduced in aortas of apolipoprotein E-null mice and that ADAMTS-5 activity affects proteoglycan-mediated lipoprotein retention.<sup>11</sup> We have also shown that on stent-induced vascular injury, a reduction in ADAMTS-1 and ADAMTS-5 contributes to an increase in large aggregating proteoglycans, notably aggrecan and versican.<sup>12</sup> Similarly, the absence of ADAMTS-5 leads to

Received on: December 22, 2017; final version accepted on: March 19, 2018.

From the King's British Heart Foundation Centre, King's College London, United Kingdom (M.F., J.B.-B., U.M., R.L., A.D., F.B., M.L., N.C., A.J., T.B., X.Y., M.M.); St George's University of London, NHS Trust, United Kingdom (M.F., M.J.); and Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, NY (M.F., M.M.).

The online-only Data Supplement is available with this article at <http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.117.310562/-/DC1>.

Correspondence to Manuel Mayr, MD, PhD, King's British Heart Foundation Centre, King's College London, London WC2R 2L, United Kingdom. E-mail [manuel.mayr@kcl.ac.uk](mailto:manuel.mayr@kcl.ac.uk)

© 2018 The Authors. *Arteriosclerosis, Thrombosis, and Vascular Biology* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

*Arterioscler Thromb Vasc Biol* is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.117.310562

## Nonstandard Abbreviations and Acronyms

|                               |  |
|-------------------------------|--|
| <b>ADAMTS</b>                 | a disintegrin and metalloproteinase with thrombospondin motifs |
| <b>AngII</b>                  | angiotensin II   |
| <b>AsAo</b>                   | ascending aorta  |
| <b>CO6A6</b>                  | collagen type VI $\alpha$ -6                                   |
| <b>COCA1</b>                  | collagen type XII $\alpha$ -1                                  |
| <b>ECM</b>                    | extracellular matrix   |
| <b>FINC</b>                   | fibronectin  |
| <b>GuHCl</b>                  | guanidine hydrochloride  |
| <b>LRP1</b>                   | low-density lipoprotein-related protein 1                      |
| <b>MFAP5</b>                  | microfibrillar-associated protein 5                            |
| <b>MMPs</b>                   | matrix metalloproteinases                                      |
| <b>SDS</b>                    | sodium dodecyl sulfate   |
| <b>SMCs</b>                   | smooth muscle cells  |
| <b>TAA</b>                    | thoracic aortic aneurysm                                       |
| <b>TGF-<math>\beta</math></b> | transforming growth factor- $\beta$                            |

the developmental defects including myxomatous valve malformation. Mice lacking ADAMTS-5 activity cannot degrade versican during the remodeling of the valve cushion resulting in enlarged pulmonary and aortic valve cusps.<sup>13</sup> LRP1 (low-density lipoprotein-related protein 1), a widely expressed receptor, is known to mediate ADAMTS-5 clearance by promoting its endocytosis. Interestingly, LRP1 has been implicated in aneurysm formation; LRP1 deletion in SMCs profoundly augmented AsAo aneurysm formation induced by AngII.<sup>14</sup>

In the present article, we aim to characterize regional differences in ADAMTS expression in murine aortas and to explore aortic ECM changes in mice with loss of ADAMTS-5 activity. Because the ECM is an intricate protein network and alterations in proteolytic activity will induce secondary remodeling processes, we used our established proteomics approach for studying the vascular ECM.<sup>15</sup>

## Materials and Methods

An expanded Materials and Methods section is available in the [online-only Data Supplement](#). The data that support the findings of this study are available from the corresponding author on reasonable request.

## Animal Experiments

All animal procedures were performed by authorized researchers in the Cardiovascular Division, King's College London. Housing and animal care was in accordance with the UK Animals (Scientific Procedures) Act 1986. Genotyping of *Adams5*<sup>Δcat</sup> and control (*Adams5*<sup>+/+</sup>) mice was performed as previously published.<sup>11</sup> For AngII infusion, osmotic mini-pumps (Alzet, model 1004) containing AngII (1.44 mg g<sup>-1</sup> d<sup>-1</sup> dissolved in saline) were implanted in 10- to 12-week-old male *Adams5*<sup>Δcat</sup> and *Adams5*<sup>+/+</sup> mice derived from littermates of heterozygous breeders (JAX stock no. 005771, B6.129P2-*Adams5*<sup>tm1Dgen/J</sup>). Animals were euthanized after 4 weeks, and the entire aorta was excised and immediately washed in sterile PBS. The entire aorta was snap-frozen at -80°C for subsequent proteomic analysis. For gene expression analysis, aortic tissue was divided into anatomically defined regions using a scalpel under a dissecting microscope, followed by immediate storage at -80°C. Aortic diameter was monitored using ultrasound at day 0 (baseline) and after 27 days of AngII treatment using Vevo software version 1.7.

## Mouse Echocardiography

Animals were anesthetized using 5% isoflurane mixed with 1 L/min of 100% oxygen for 45 seconds to 1 minute. Mice were then placed in a supine position on a heating pad with embedded ECG registration. On adequate induction, 1% to 1.5% isoflurane mixed with 1 L/min 100% oxygen was used to maintain a steady state of sedation throughout the procedure. A rectal probe was inserted to continuously monitor the body temperature. Electrode gel was applied to the 4 paws, which were taped to the ECG electrodes. Two-dimensional echocardiographic images of cardiovascular anatomy were obtained by a single operator. Standard and modified parasternal long-axis, suprasternal, longitudinal abdominal, and transverse abdominal views were obtained using Visual Sonics Vevo 2100. Aortic root dimensions (aortic annulus, sinuses of Valsalva, and sinotubular junction) were measured in parasternal long-axis view. AsAo dimensions were measured during systole and diastole in suprasternal view where possible and modified parasternal long-axis view if suprasternal views were considered inadequate. Measurements were taken from leading edge-to-leading edge. Abdominal aorta measurements were made in the TA view. All measurements were performed offline (Vevo software version 1.7) by 2 consensus interpreters.

## Blood Pressure Monitoring

The blood pressure was directly measured via an implantable radio-telemetry device. An average of 200 values were acquired every 5 minutes for 18 to 20 hours. Blood pressure was monitored using telemetry probes 2 days before mini-pump implantation and at days 5 and 27 of AngII infusion.

## ECM Protein Extraction From Murine Aortas

Aortic samples were partially thawed and diced into smaller pieces to aid the removal of plasma contaminants and for the effective extraction of ECM proteins.<sup>16,17</sup> ECM protein enrichment of aortic samples was performed using an adaptation of our previously published 3-step extraction method, involving sequential incubation with 0.5 mol/L NaCl for 2 hours, 0.08% sodium dodecyl sulfate (SDS) for 2 hours, and a final incubation with 4 mol/L guanidine hydrochloride (GuHCl) for 48 hours. After precipitation of GuHCl extracts, protein samples were enzymatically deglycosylated and subjected to in-solution trypsin digestion. Details are given in Online Methods in the [online-only Data Supplement](#).

## Proteomics Analysis of ECM Extracts

After deglycosylation (protocol details are provided in the Online Methods in the [online-only Data Supplement](#)), digested peptides were separated on a nanoflow liquid chromatography system, and GuHCl extracts were injected for liquid chromatography-tandem mass spectrometry analysis into a Q Exactive HF mass spectrometer (Thermo Fisher Scientific) for discovery proteomics. Acquisition was performed as previously described.<sup>15</sup> For targeted MS analysis, an isolation list was created for proteotypic peptides of mouse versican and GuHCl extracts were analyzed via parallel reaction monitoring mode on a Q Exactive HF mass spectrometer. Details are given in Online Methods in the [online-only Data Supplement](#).

## Total Protein Extraction From Murine Aortas

Mouse aortic samples were homogenized in the presence of 300  $\mu$ L of tissue lysis buffer (0.152 g of Tris, 0.33 g of NaCl, 0.038 g of EGTA, 0.073 g of EDTA, 500  $\mu$ L of Triton, and 250  $\mu$ L of 20% SDS) at pH 7.4. Protein concentration was measured using BCA protein assay kit, and Western blots were performed following the protocol in the Online Methods in the [online-only Data Supplement](#).

## Cell Culture of Human Arterial SMCs

Samples of internal mammary artery were collected from patients undergoing bypass graft surgery at Leeds General Infirmary, conforming with the principles outlined in the Declaration of Helsinki.

Arterial SMCs were extracted and expanded using an explant technique.<sup>18</sup> SMCs were seeded into 6-well tissue culture plates. Twenty-four hours after seeding, cells were cultured in serum-free DMEM for 1 hour. Ten nanogram per milliliter of human TGF- $\beta$ 1 (R&D systems) was diluted in serum-free DMEM (1195-045; Gibco), and cells were treated for 24 hours. Changes in versican expression after stimulation were measured by real-time quantitative PCR using TaqMan assay for the corresponding human target. Major Resources Table is given in the [online-only Data Supplement](#).

### Quantitative Real-Time PCR

RNA extraction was performed using the miRNeasy Mini Kit (Qiagen) following the manufacturers' protocol. RNA concentration (Abs 260 nm) and purity (260/280) were measured in 1  $\mu$ L of eluted RNA using spectrophotometry (NanoDrop ND-1000; Thermo Scientific). RNA integrity was evaluated using the Agilent Bioanalyzer System and considered acceptable if the RNA integrity number was >7. The RNA was then reverse transcribed using random hexamers with SuperScript VILO MasterMix (Invitrogen) according to manufacturers' protocol, with sample preparation being performed on a StarChill PCR rack to maintain low temperature. The reverse transcription product was diluted 1:15 to 1:25 using RNase-free water. TaqMan hydrolysis probes were used for quantitative PCR analysis. Data were analyzed using ViiA 7 software (Applied Biosystems). A minimum of 2 reference genes was used throughout the study, and stability of RNA isolation, reverse transcription, and quantitative PCR was determined by variability of and correlation between reference genes. Analysis of stability was also performed using geNorm, a commonly used algorithm for validation of reference gene stability based on the comparative cycle-to-threshold method.<sup>19</sup> Relative amounts of the targets were calculated using the  $2^{-\Delta\Delta C_q}$  method,<sup>20</sup> with statistical analysis performed on  $\Delta C_q$  values.

### Immunofluorescence Staining in Murine AsAo

Murine aortas were fixed for 24 hours in 4% formaldehyde at room temperature. In brief, 3- $\mu$ m sections were deparaffinized in xylene and rehydrated in graded ethanol. The slides were unmasked using hot sodium citrate buffer (pH 6.0), then permeabilized for 20 minutes in 0.1% Triton X-100. Sections were blocked with 10% serum at room temperature, before incubation with primary antibodies against LRP1 and  $\alpha$ -smooth muscle actin or species-matched isotypes overnight at 4°C. After washes in PBST, sections were incubated for 1 hour at room temperature with the secondary antibody. Nuclei were stained using DAPI for 10 minutes. Sections were visualized under a Nikon spinning disk confocal microscope (KO.18), and images were acquired using NIS-elements 4.0 software. Scale bars are included in the images as indicated in the figure legends.

### Transfection Experiments in Human Aortic SMCs

Human aortic SMCs were purchased from LONZA and cultured in SMC medium (cc-3183; LONZA) with 5% fetal bovine serum (LONZA). SMCs were seeded into 6-well tissue culture plates, and 24 hours after seeding, cells were transfected with 50 nmol/L of *LRP1* siRNA (Dharmacon, M-004721-01-0005, targeted sequences: GCAAGAAGCCGGAGCAUGA, GAACAAACACACUGGCUAA, GCUAUGAGUUUAAGAAGUU, GCGCAUCGAUCUUCACAAA) by using lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. Nontargeting siRNA served as control (Dharmacon, D-001206-14-05, targeted sequences: UAAGGCUAUGAAGAGAUAC, AUGUAUUGGCCUGUAUUAG, AUGAACGUGAAUUGCUCAA, UGGUUUACAUGUCGACUAA). Cells were incubated for 6 hours in Opti-MEM (11058-021; Gibco) with lipofectamine and siRNAs. After removal of transfection medium, SMCs were incubated with SMC medium with 5% fetal bovine serum for 48 hours. Then, cells were cultured in serum-free SMC medium for 24 hours. Medium was collected for protein measurements. Cells were harvested for quantitative PCR and Western blot analyses. Major Resources Table is given in the [online-only Data Supplement](#). Four milliliters of conditioned

media was concentrated using 0.5 mL columns with 3 kDa filter (Amicon Ultra Centrifugal Filter Device; 3 kD). Five hundred milliliters of samples was added each time and centrifuged at 14000g for 40 minutes at 4°C until the residual volume was around 30  $\mu$ L. Samples were then washed twice using 500  $\mu$ L of 0.1% SDS each time. Protein concentrates were then used for Western blots. After conditioned medium collection, cell layers were washed 3 $\times$  with cold PBS to remove the residual medium. Cells were scraped off in cold PBS and spun for 1 minute at 15000g. One hundred milliliters of 1 $\times$  lysis buffer with 1:100 proteinase inhibitors, 25 mmol/L of EDTA was added to cell pellets. After resuspension, lysed cell pellets were vortexed and incubated for 20 minutes on ice. Protein concentration was measured using a BCA protein assay kit before Western blot analyses.

### Immunofluorescence Staining in Human Aortic Specimen

Human aortic tissues were collected from patients undergoing AsAo replacement surgery at St. George's Hospital according to the local Research Ethics Committee (London, REC No 08/H0803/257). Aortic tissues were fixed in 10% formalin and then embedded with paraffin. For antigen retrieval, chondroitinase ABC was applied on 5  $\mu$ m tissue sections for 2 hours at 37°C. After blocking with 10% fetal bovine serum for 1 hour, sections were comincubated with primary antibodies to full-length versican and versican neopeptide DPEAAE overnight at 4°C. Species-matched isotype IgGs were used as negative controls. The appropriate secondary antibody was used for 1 hour at room temperature. Nuclei were stained with DAPI (1:1000 dilution) for 5 minutes. The images were visualized with an inverted Nikon Spinning disc confocal unit and acquired using NIS-elements 4.0 software.

### Statistical Analysis

GraphPad Prism software 7 was used for the analysis. For each experiment, Shapiro-Wilk normality test was applied to test the distribution of the data. If the data were not normally distributed, a non-parametric test was used. The appropriate tests and post hoc analysis were chosen according to the data distribution as specified in each figure legend. Data are represented as mean $\pm$ SD. For proteomics, statistical analysis was not performed if a protein was undetectable in the majority of samples from both groups compared. This is denoted as not applicable. Data from discovery proteomics are presented as normalized total ion current. Data obtained from targeted proteomics are presented as peak area and adjusted according to the total ion intensity for each sample. The aortic diameters are represented as box and whisker plots, with 75th and 25th percentiles; bars represent maximum and minimum values. Differences were assessed using a 2-way ANOVA and Sidak post hoc test. For all statistical analysis,  $P < 0.05$  was deemed significant.

## Results


### ADAMTS Expression in the Murine Aorta

Transcript levels of *Adamts5* were higher in the aortic arch compared with the other aortic regions, along with transcript levels of the large aggregating proteoglycans versican (*Vcan*) and aggrecan (*Acan*), 2 ADAMTS-5 substrates, which were most highly expressed in the arch. Expression of *Tgfb1* and 2 and *Tgfb2* and 3 were also higher in the arch compared with the abdominal aorta. In contrast, *Adamts1* and *Adamts4* and hyaluronan and proteoglycan link protein 1 (*Hapln1*) showed lower transcript levels in the arch compared with other regions of the murine aorta (Figure 1).

### Aortic Dilatation in *Adamts5*<sup>Δcat</sup> Mice

Loss of ADAMTS-1 has recently been implicated in TAA.<sup>3</sup> Thus, we assessed aortic dilatation in mice lacking the catalytic





**Figure 1.** Gene expression along the murine aorta. Relative gene expression of *Adamts1* (a disintegrin and metalloproteinase with thrombospondin motifs 1), *Adamts4* and *Adamts5*, versican (*Vcan*), aggrecan (*Acan*) and hyaluronan and proteoglycan link protein 1 (*Hapln1*), and *Tgfb1* (transforming growth factor- $\beta$ 1), *Tgfb2* and *Tgfb3* and *Tgfr1*, *Tgfr2* and *Tgfr3* in the aortic arch (A), descending (D) and abdominal (Ab) aorta (n=6).  $\beta$ -actin was used as reference gene. Gene expression levels in the arch served as reference. Values are given as mean $\pm$ SD; \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 by Friedman test with Dunn post hoc comparison.

domain of *Adamts5* (*Adamts5*<sup>Δcat</sup>).<sup>21</sup> Hypertension was induced in *Adamts5*<sup>+/+</sup> and *Adamts5*<sup>Δcat</sup> mice by AngII infusion for 4 weeks (Figure I in the online-only Data Supplement). AngII treatment was associated with increased aortic dilatation in *Adamts5*<sup>Δcat</sup> mice (Figure 2A and 2B); significant differences compared with *Adamts5*<sup>+/+</sup> were observed both in the aortic root, in particular in the aortic annulus, and the AsAo. Notably, the increased aortic dilatation in *Adamts5*<sup>Δcat</sup> mice occurred despite an attenuated rise in systolic and diastolic blood pressure after 27 days of AngII treatment (Figure 2C). The aortic phenotype and the blood pressure changes in *Adamts5*<sup>Δcat</sup> mice bear a strong resemblance to the one recently described in mice with *Adamts1* haploinsufficiency.<sup>3</sup>


### Vascular Substrates of ADAMTS-1 and ADAMTS-5

To identify vascular substrates of ADAMTS-1 and ADAMTS-5, murine aortas were subjected to overnight incubation with either ADAMTS-1 or ADAMTS-5 (50 pmol L<sup>-1</sup> mg<sup>-1</sup> tissue at 37°C; Figure 3A). Aortas incubated in buffer only served as control. The proteins released into the digestion buffer were separated by SDS-PAGE, subjected to in-gel tryptic digestion, and analyzed by liquid chromatography-tandem mass spectrometry. Among the identified extracellular proteins, proteins with differential release on digestion

by ADAMTS-1 and -5 include known substrates such as versican (CSPG2; Figure 3B; Table I in the online-only Data Supplement). Detailed examination of the gel-liquid chromatography-tandem mass spectrometry data revealed the presence of proteolytic products (Figure 3C), that is, for CSPG2, CO6A6 (collagen type VI  $\alpha$ -6), FINC (fibronectin), and LRP1. However, proteolytic cleavage may occur without differential release into the digestion buffer, that is, a higher number of MS/MS spectra for biglycan (PGS1) and COCA1 (collagen type XII  $\alpha$ -1) were identified in-gel segments below the expected molecular weight of the full-length protein indicative of proteolysis. Again, this includes known substrates of ADAMTS-5, such as PGS1.<sup>22</sup>

### Proteomics Analysis of Aortas From AngII-Treated Wild-Type and *Adamts5*<sup>Δcat</sup> Mice


To analyze the changes in ECM composition on loss of ADAMTS-5 activity, aortas from AngII-treated *Adamts5*<sup>+/+</sup> and *Adamts5*<sup>Δcat</sup> mice were subjected to a 3-step sequential extraction procedure: pretreatment with 0.5 mol/L NaCl followed by decellularization with 0.08% SDS and a final incubation step with 4 mol/L GuHCl to solubilize the ECM (Figure 4A). Using a discovery proteomics approach, along with MFAP5 (microfibrillar-associated protein 5),



**Figure 2.** Aortic dilatation in Adamts5<sup>Δcat</sup> (mice lacking the catalytic domain of a disintegrin and metalloproteinase with thrombospondin motifs 5) mice. **A**, Representative ultrasound images. Red dashed lines mark areas considered for aortic diameter measurements. **B**, Maximal diameters of the aortic ring (AoR; aortic annulus [AoAn] and sinuses of Valsalva [SiVa]), ascending aorta (AsAo), and abdominal aorta (AbAo) from AngII (angiotensin II)-treated (Adamts5<sup>+/+</sup>, n=6 and Adamts5<sup>Δcat</sup>, n=5) and untreated (Adamts5<sup>+/+</sup>, n=9 and Adamts5<sup>Δcat</sup>, n=9) mice. Adamts5<sup>+/+</sup> and Adamts5<sup>Δcat</sup> mice are represented using burgundy and purple color, respectively. **C**, Systolic and diastolic blood pressure measurements at day 0, 5, and after 27 days of AngII infusion in Adamts5<sup>+/+</sup> (n=6) and Adamts5<sup>Δcat</sup> mice (n=4). Data points are mean±SD; P values derived from a 2-way ANOVA (aortic diameter) and 1-way ANOVA (blood pressure) with Sidak correction. \*P<0.05, \*\*P<0.01.

versican (CSPG2) was returned as more abundant in aortas of AngII-treated Adamts5<sup>Δcat</sup> mice (Figure 4B; Table II in the [online-only Data Supplement](#)). Subsequent targeted proteomics analysis using both N-terminal and C-terminal proteotypic peptides corroborated that versican was elevated in AngII-treated Adamts5<sup>Δcat</sup> mice (Figure 4C; Table III in the [online-only Data Supplement](#)). TGF-β1 is known to enhance versican expression.<sup>23</sup> Human arterial SMCs stimulated with

TGF-β1 showed a rise in versican transcripts (Figure 4D). Notably, higher levels of versican were associated with increased protein abundance of TGF-β in aortas of AngII-treated Adamts5<sup>Δcat</sup> mice (Figure 4E; Figure II in the [online-only Data Supplement](#)). Gene expression levels of *Tgfb1* and 2 and their receptors *Tgfb1-3* were significantly higher in Adamts5<sup>Δcat</sup> mice at baseline (Figure III in the [online-only Data Supplement](#)). Interestingly, *Adamts1* transcripts were



**Figure 3.** Proteomics to identify vascular targets of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-1 and -5. **A**, Murine aortas were subjected to overnight incubation with either 50 pmol/L ADAMTS-1 (+ATS1) or 50 pmol/L ADAMTS-5 (+ATS5) at 37°C. Aortic explants incubated in buffer served as control. **B**, Unsupervised hierarchical clustering of the differentially released ECM (extracellular matrix) proteins (55 proteins were tested by Kruskal–Wallis test, and 13 were found differentially regulated;  $P < 0.05$ ) in the supernatants of mouse aortas as identified by proteomics ( $n = 3$ ). The blue–red heat map represents normalized spectral counts highlighting differences in proteins released from aortic explants. **C**, Spectral evidence for fragmentation. The color-coded heat map represents the total number of identified spectra in each gel band and visualizes the fragmentation of ECM proteins. Color scales for heat maps represent maximum and minimum number of spectra identified in each group. COCA1 indicates collagen type XII a1 chain; CO6A6, collagen type VI a6 chain; CSPG2, versican; FINC, fibronectin; LC-MS/MS, liquid chromatography–tandem mass spectrometry; LRP1, low-density lipoprotein receptor-related protein 1; and PGS1, biglycan.

markedly elevated in *Adamts5<sup>Acat</sup>* mice, suggesting a compensatory increase of ADAMTS-1 on loss of ADAMTS-5 activity.

### Versican Cleavage in Aortas of *Adamts5<sup>Acat</sup>* Mice

Versican was the most differentially regulated ECM protein in aortas from *Adamts5<sup>Acat</sup>* mice treated with AngII (Figure 4B). It was also returned as one of the major substrates of ADAMTS-1 and -5 in the analysis of aortic explants (Figure 3B). Therefore, we focused on ADAMTS-mediated versican processing. ADAMTS activity results in the release of a specific versican fragment ending with the DPEAAE<sup>441</sup> sequence,<sup>11,24</sup> named versikine.<sup>25</sup> This signature cleavage site of ADAMTS activity can be detected using a neoepitope antibody (Figure 5A). As expected, aortas from *Adamts5<sup>Acat</sup>* mice displayed reduced versikine; the 65 kDa band is representative of versikine (Figure 5B). Even after AngII treatment, less versikine was observed in *Adamts5<sup>Acat</sup>* mice. This highlights the dependence on ADAMTS-5 activity for versicanolysis in AngII-induced aortic remodeling (Figure 5C).


### Compensatory Increase of ADAMTS-1 in Aortas of *Adamts5<sup>Acat</sup>* Mice

Because of different processing, ADAMTS-1 can be found in 2 forms, a larger cell layer and ECM-associated version and

a smaller, soluble version (Figure 5A).<sup>26</sup> Immunoblotting for ADAMTS-1 performed on total aortic tissue lysates revealed that the loss of ADAMTS-5 activity was accompanied by an increase in the smaller, soluble form of ADAMTS-1 (65 kDa). This was exacerbated after AngII treatment. In contrast, the larger, ECM-associated ADAMTS-1 form (79 kDa) was detected almost exclusively in the wild-type group. The increase in soluble ADAMTS-1 suggests a cross-talk between members of the ADAMTS protease family; however, this compensatory upregulation did not result in the complete rescue of ADAMTS-mediated versican cleavage (Figure 5C).

### Reduced LRP1 in AngII-Treated Aortas of *Adamts5<sup>Acat</sup>* Mice

To further investigate the molecular mechanisms, associated with the loss of ADAMTS-5 activity, we analyzed LRP1, a receptor implicated in the endocytosis of ADAMTS proteases. LRP1 was identified as a vascular target of ADAMTS-1 and -5 (Figure 3). LRP1 was profoundly reduced in aortas of AngII-treated *Adamts5<sup>Acat</sup>* mice (Figure 5C; Figure IV in the online-only Data Supplement). LRP1 staining was mainly observed in SMCs of mouse aortas (Figure 6A). Next, we silenced *LRP1* expression in primary human aortic SMCs. Silencing LRP1 did not affect *ADAMTS1* gene expression but markedly reduced expression of *ADAMTS5* (Figure 6B). Consequently,



**Figure 4.** ECM (extracellular matrix) proteomics of AngII (angiotensin II)-treated murine aortas. **A**, ECM proteomics workflow. **B**, ECM extracts of the entire aorta from AngII-treated *Adamts5*<sup>+/+</sup> (a disintegrin and metalloproteinase with thrombospondin motifs; *n*=6) and *Adamts5*<sup>Δcat</sup> (*n*=5) mice were analyzed using discovery proteomics. Black dots represent proteins differentially regulated between the groups (*P*<0.05). Statistical significance was calculated using Mann–Whitney test (76 ECM and ECM-associated proteins were tested, and 2 were found differentially regulated). **C**, Two different proteotypic peptides (ie, N terminal and C terminal) were chosen to validate levels of versican in aortic tissue using targeted proteomics. Peak area values of versican in *Adamts5*<sup>+/+</sup> served as reference for N-terminal and C-terminal peptides. Statistical significance was calculated using unpaired Student *t* test. **D**, Internal mammary artery smooth muscle cells (SMCs) from 4 donors were incubated with TGF (transforming growth factor)-β1. Gene expression of versican was assessed by quantitative PCR. Gapdh was used as internal control. Statistical significance was calculated using unpaired Student *t* test. **E**, Immunoblots performed on total protein lysates reveal an increase in full-length versican and TGF-β in aortas of AngII-treated *Adamts5*<sup>Δcat</sup> mice (*n*=4 per group). CSPPG2 denotes versican; GuHCl, guanidine hydrochloride; LC-MS/MS, liquid chromatography–tandem mass spectrometry; and MFAP5, microfibrillar-associated protein 5.

versikine was barely detectable in the conditioned media of SMCs transfected with an siRNA to *LRP1*. Moreover, in agreement with our results in AngII-treated *Adamts5*<sup>Δcat</sup> mice, we observed a concomitant increase in ADAMTS-1 on repression of *LRP1* (Figure 6C; Figure V in the [online-only Data Supplement](#)). Thus, these in vitro experiments complement our in vivo findings and establish a link between *LRP1* and ADAMTS-5–mediated versican cleavage.

### Versican Cleavage in Human Aortic Aneurysms


Although differences in versican abundance have been reported in human abdominal aortic aneurysms,<sup>27</sup> versikine has not been localized yet in human AsAo aneurysms. Immunofluorescence staining was performed for versican and

versikine. Versican staining was seen throughout the aortic wall, whereas versikine was localized predominantly in the outer media and the subintimal layer of the AsAo aneurysm (Figure 6D). These data confirm the presence of ADAMTS-specific versican cleavage in human ascending TAA tissue.

### Discussion

We have characterized regional differences in ADAMTS expression along the murine aorta and used proteomics to evaluate the effect of loss of ADAMTS-5 activity on aortic ECM remodeling. We demonstrated that deficiency of ADAMTS-5 affects ADAMTS-1 gene expression, protein abundance, and processing and resulted in aortic dilatation similar to the phenotype recently described in *Adamts1*-haploinsufficient mice.<sup>3</sup>





**Figure 5.** ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-1 cannot compensate for the lack of ADAMTS-5 activity. **A, Left.** Schematic representation of ADAMTS-mediated versican processing. The signature cleavage site for ADAMTS activity gives rise to an N-terminal versican fragment (versikine) and is recognized by a neopeptide antibody to the DPEAAE amino acid sequence. **Right.** Schematic representation of ADAMTS-1 processing. Processing by MMPs (matrix metalloproteinases) gives rise to a truncated, soluble form of ADAMTS-1 (65 kDa). **B, C.** Immunoblots using neopeptide antibodies to versikine were performed on aortic ECM (extracellular matrix) extracts from untreated and AngII (angiotensin II)-treated mice ( $n=5$  per group). Immunoblots for ADAMTS-1 and LRP1 (low-density lipoprotein-related protein 1) were performed on total protein lysates of untreated and AngII-treated mice ( $n=5$  and  $n=4$  per group, respectively). Densitometry for the versican V1 fragment (versikine) and ADAMTS-1. Bars represent mean $\pm$ SD. Statistical significance was calculated using unpaired Student  $t$  tests. \* $P<0.05$ , \*\* $P<0.01$ .

### ADAMTS Proteases in Murine Aortas


ADAMTS-1 and ADAMTS-5 are highly expressed in murine aortas. We have previously demonstrated that ADAMTS-5 is the most potent protease associated with versican cleavage in the murine aorta.<sup>11</sup> Loss of ADAMTS-5 also results in the accumulation of aggrecan.<sup>12</sup> To investigate the contribution of ADAMTS-5 in ECM remodeling during aortic aneurysm formation, a mouse model lacking ADAMTS-5 activity was used. Administration of AngII for 4 weeks exacerbated aortic dilatation in Adamts5 <sup>$\Delta$ cat</sup> mice, with a significantly greater diameter in the AsAo where Adamts5 expression is the highest in

Adamts5<sup>+/+</sup> mice. Moreover, Adamts5 <sup>$\Delta$ cat</sup> mice showed a lower blood pressure in response to AngII stimulation. Interestingly, a recent study reported a similar reduction in blood pressure in Adamts1-haploinsufficient mice.<sup>3</sup> Also other ADAMTS proteases have been implicated in the vasculature and the regulation of blood pressure.<sup>28</sup>

### Proteomics to Identify Vascular Substrates

In the current study, we used proteomics for the analysis of aortic ECM changes associated with loss of ADAMTS-5 activity. By using proteomics, we found that versican was





**Figure 6.** Effects of LRP-1 (low-density lipoprotein-related protein 1) and detection of versikine in human ascending aortic aneurysms. **A**, LRP1 localization in the ascending aorta of *Adamts5<sup>Δcat</sup>* (mice lacking the catalytic domain of a disintegrin and metalloproteinase with thrombospondin motifs 5) mice. Colocalization of LRP1 (Alexa 647, displayed in red) and  $\alpha$ SMA (Alexa 568, displayed in green) in the mouse aorta as visualized by immunofluorescence. Elastin fibers are in white (autofluorescence captured with 488 nm laser excitation). Control sections stained with isotype IgGs. Magnification  $\times 60$ , scale bars=10 mm. **B**, Relative gene expression of *ADAMTS1*, *LRP1*, *ADAMTS5*, and *VCAN* in human aortic smooth muscle cells (SMCs) treated for 72 h with *LRP1* siRNA ( $n=3$ ).  $\beta$ -actin was used as reference gene. Data points are mean $\pm$ SD. Statistical significance was calculated using a paired Student *t* tests. \* $P<0.05$ . **C**, Immunoblotting performed on cell lysate and conditioned media after transfection ( $n=3$ ). Silencing LRP1 results in a decrease in versikine and an increase in ADAMTS-1 in the conditioned media. **D**, Localization of versican (Alexa568, displayed in green) and versikine (Alexa 647, displayed in red) in human ascending aortic aneurysms as visualized by immunofluorescence. Magnification  $\times 20$ , scale bar=200 mm and  $\times 60$ , scale bar=20 mm.

more abundant in AngII-treated *Adamts5<sup>Δcat</sup>* mice. Versican is one of the most abundant large aggregating proteoglycans in the aorta.<sup>16</sup> Tissue accumulation of versican has been linked to the loss of fibrous ECM organization.<sup>29</sup> Because we failed to detect changes in versican gene expression in *Adamts5<sup>Δcat</sup>* mice (data not shown), differences in versican protein abundance are most probably related to post-translational processing rather than protein synthesis. Versican is a well-known substrate of ADAMTS proteases.<sup>30</sup> The release of versikine was also observed after incubation of human aortic tissues with either ADAMTS-1 or ADAMTS-5.<sup>11</sup> The absence of the catalytic activity of ADAMTS-5 seems to result in the build-up of unprocessed versican in the aortic wall, as previously observed in valve tissue of *Adamts5<sup>Δcat</sup>* mice.<sup>13</sup>

### ADAMTS-Mediated Versicanolysis

Versican can be cleaved by different proteases including MMPs,<sup>31</sup> plasmin,<sup>32</sup> and several members of the ADAMTS family. The latter harbor sequence motifs specific to large aggregating proteoglycans, including versican.<sup>16</sup> The neopeptide DPEAAE at position 441 of versican is generated after ADAMTS cleavage.<sup>25</sup> The neopeptide antibody recognizes only the cleaved product of versican, corresponding to the N terminus of the proteoglycan.<sup>25</sup> This fragment was reduced in *Adamts5<sup>Δcat</sup>* mice, which is in agreement with our previous report.<sup>11</sup> As demonstrated in this study, this effect is exacerbated after AngII infusion; chronic infusion of AngII enhanced the release of versikine in murine aortas. In AngII-treated *Adamts5<sup>Δcat</sup>* mice, immunoblotting revealed

a marked reduction of the ADAMTS-specific DPEAAE neopeptide demonstrating the importance of ADAMTS-5 for versican cleavage. Versikine has been suggested to stimulate SMC migration and induce cell apoptosis during development.<sup>33,34</sup> Little residual ADAMTS activity was detectable in aortas of AngII-treated *Adamts5<sup>Δcat</sup>* mice. The latter is most likely attributable to ADAMTS-1, which was increased in *Adamts5<sup>Δcat</sup>* mice. ADAMTS-1 is known to be processed into 2 active forms: (1) an ECM associated and (2) a soluble form, generated after MMP cleavage of the thrombospondin domain at the C terminus. The loss of ADAMTS-5 activity led to a rise in the soluble form of ADAMTS-1, and this effect was exacerbated after AngII treatment. The removal of the last thrombospondin domain renders ADAMTS-1 more similar to ADAMTS-5, suggesting that the release of soluble ADAMTS-1 could be a compensatory response to the loss of ADAMTS-5. ADAMTS-1, however, does not seem to be sufficient to compensate for the lack of ADAMTS-5 activity, at least with regards to versican cleavage.

### Effects on TGF-β

The increase in total versican levels was associated with a concomitant upregulation of TGF-β in *Adamts5<sup>Δcat</sup>* mice after AngII treatment. TGF-β is known to induce the expression of different proteoglycans, including versican.<sup>23</sup> In line with this finding, stimulation of arterial SMCs with TGF-β1 led to an increase in versican expression. Interestingly, it has also been shown that the latent form of TGF-β can be associated and subsequently activated by the C-terminal region of ADAMTS-1, thereby enhancing the inflammatory response in liver fibrosis.<sup>35</sup> In agreement with these results, we found a direct correlation between ADAMTS-1 and TGF-β regulation in ADAMTS-5<sup>Δcat</sup> mice on AngII treatment. The increased levels of versican, TGF-β, and ADAMTS-1 were accompanied by an increased aortic dilatation in these mice after AngII treatment. Dysregulation of TGF-β has been linked to aneurysm development.<sup>36,37</sup> However, the mechanisms of TGF-β-mediated aneurysm formation have not completely elucidated yet. The present study highlights an effect of ADAMTS activity on TGF-β bioavailability.

### Regulation by LRP1

LRP1 has previously been implicated in aortic aneurysm formation in humans and mice<sup>14,38,39</sup>; however, the exact mechanisms are unclear. LRP1 is involved in different cellular processes, such as lipid homeostasis, signal transduction, and endocytosis.<sup>40,41</sup> LRP1 also acts as a protease sink responsible for cellular uptake of ADAMTS-5 from the extracellular space.<sup>42</sup> Moreover, LRP1 can bind TGF-β1 and TGF-β2 and thereby inhibit cell proliferation and regulate vascular remodeling, respectively.<sup>43</sup> After AngII treatment, LRP1 was less abundant in aortas of *Adamts5<sup>Δcat</sup>* mice. This was accompanied by an increase in the short soluble form of ADAMTS-1 as a possible mechanism to compensate for the lack of ADAMTS-5. This coordinated regulation is consistent with a feedback mechanism between ADAMTS-1 and LRP1 and a compensatory downregulation of LRP1 in *Adamts5<sup>Δcat</sup>* mice to increase the extracellular availability of ADAMTS proteases.

Silencing LRP1 in human aortic SMCs reduced *ADAMTS5* expression and resulted in a loss of ADAMTS-mediated versican cleavage. Again, this was accompanied by an increase of ADAMTS-1 in the conditioned media. These findings expand on a previous report that the deletion of *Lrp1* expression in SMCs augmented AsAo dilatation in AngII-treated mice.<sup>14</sup>

### Limitations of the Study

A mouse model of AngII infusion was used to study the effects of ADAMTS-5 on aortic dilatation, which may not recapitulate all aspects of human aneurysmal disease, in particular with regards to hemodynamics and mechanotransduction.<sup>44,45</sup> Also, the relative importance of different members of the ADAMTS family may differ between species. In human aneurysmal disease, previous studies have shown increased protein and transcript levels of ADAMTS-1 and -4 in TAA.<sup>10,46</sup> Consistent with our findings, a recent study reported decreased *ADAMTS5* expression and increased deposition of proteoglycans, such as aggrecan and versican in human TAA.<sup>8</sup> Finally, changes in ADAMTS activity are likely to be associated with the proteolysis of other proteins apart from versican.

### Conclusions

At present, the clinical management of aneurysms is hampered by our limited knowledge about the cause and pathogenetic mechanisms involved in the disease. Evidence is emerging that ECM processing by members of the ADAMTS protease family could play an important role in the progression of aortic dilatation.<sup>3</sup> The present study takes advantage of proteomics to define vascular substrates of ADAMTS proteases. LRP1, which has been involved in aneurysm pathology in both human and mice, seems to be linked to ADAMTS-5 and ADAMTS-5-mediated versican cleavage. In mice lacking ADAMTS-5 activity, AngII infusion results in decreased versicanolysis, an increase in full-length versican and TGF-β, but reduced LRP1 compared with wild-type controls. Mice lacking ADAMTS-5 activity also showed increased aortic dilatation in response to AngII infusion despite a lower blood pressure. A compensatory rise in ADAMTS-1 could not prevent aortic dilatation in *Adamts5<sup>Δcat</sup>* mice, suggesting the greater relative importance of ADAMTS-5 in this context. Further studies are needed to explore the ADAMTS protease family as a target for therapeutic approaches aimed to reduce or halt dilatation of the aorta resulting in dissection.

### Acknowledgments

All authors have read and approved the article. We thank Dr Karen E Porter (Leeds, United Kingdom) for providing extracts from human arterial smooth muscle cells.

### Sources of Funding

M. Mayr is a British Heart Foundation (BHF) Chair Holder (CH/16/3/32406) with BHF programme (RG/16/14/32397) and project grant support (PG/17/48/32956). The research was supported by National Institute of Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London in partnership with King's College Hospital. The study was also supported by St. George's Hospital Charitable Foundation, University of London, and by an excellent initiative (Competence Centers for Excellent Technologies



[COMET]) of the FFG (Austrian Research Promotion Agency): Research Center of Excellence in Vascular Ageing-Tyrol, VASCage (K-Project No. 843536) funded by BMVIT (Federal Ministry for Transport, Innovation and Technology), BMWFW (Federal Ministry of Science, Research and Economy), the Wirtschaftsagentur Wien, and Standortagentur Tirol.

## Disclosures

None.

## References

- Bonderman D, Gharehbaghi-Schnell E, Wollenek G, Maurer G, Baumgartner H, Lang IM. Mechanisms underlying aortic dilatation in congenital aortic valve malformation. *Circulation*. 1999;99:2138–2143.
- He R, Guo DC, Sun W, Papke CL, Duraisamy S, Estrera AL, Safi HJ, Ahn C, Buja LM, Arnett FC, Zhang J, Geng YJ, Milewicz DM. Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms. *J Thorac Cardiovasc Surg*. 2008;136:922–929.e1–929. doi: 10.1016/j.jtcvs.2007.12.063.
- Oller J, Méndez-Barbero N, Ruiz EJ, et al. Nitric oxide mediates aortic disease in mice deficient in the metalloproteinase Adamts1 and in a mouse model of Marfan syndrome. *Nat Med*. 2017;23:200–212. doi: 10.1038/nm.4266.
- Jones JA, Spinale FG, Ikonomidis JS. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. *J Vasc Res*. 2009;46:119–137. doi: 10.1159/000151766.
- Shen M, Lee J, Basu R, Sakamuri SS, Wang X, Fan D, Kassiri Z. Divergent roles of matrix metalloproteinase 2 in pathogenesis of thoracic aortic aneurysm. *Arterioscler Thromb Vasc Biol*. 2015;35:888–898. doi: 10.1161/ATVBAHA.114.305115.
- Ikonomidis JS, Jones JA, Barbour JR, Stroud RE, Clark LL, Kaplan BS, Zeeshan A, Bavaria JE, Gorman JH III, Spinale FG, Gorman RC. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. *J Thorac Cardiovasc Surg*. 2007;133:1028–1036. doi: 10.1016/j.jtcvs.2006.10.083.
- Ren P, Hughes M, Krishnamoorthy S, Zou S, Zhang L, Wu D, Zhang C, Curci JA, Coselli JS, Milewicz DM, LeMaire SA, Shen YH. Critical role of ADAMTS-4 in the development of sporadic aortic aneurysm and dissection in mice. *Sci Rep*. 2017;7:12351. doi: 10.1038/s41598-017-12248-z.
- Cikach FS, Koch CD, Mead TJ, Galatioto J, Willard BB, Emerton KB, Eagleton MJ, Blackstone EH, Ramirez F, Roselli EE, Apte SS. Massive aggrecan and versican accumulation in thoracic aortic aneurysm and dissection. *JCI Insight*. 2018;3:1–16.
- Kenagy RD, Min SK, Clowes AW, Sandy JD. Cell death-associated ADAMTS-4 and versican degradation in vascular tissue. *J Histochem Cytochem*. 2009;57:889–897. doi: 10.1369/jhc.2009.953901.
- Ren P, Zhang L, Xu G, Palmero LC, Albini PT, Coselli JS, Shen YH, LeMaire SA. ADAMTS-1 and ADAMTS-4 levels are elevated in thoracic aortic aneurysms and dissections. *Ann Thorac Surg*. 2013;95:570–577. doi: 10.1016/j.athoracsur.2012.10.084.
- Didangelos A, Mayr U, Monaco C, Mayr M. Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. *J Biol Chem*. 2012;287:19341–19345. doi: 10.1074/jbc.C112.350785.
- Suna G, Wojakowski W, Lynch M, et al. Extracellular matrix proteomics reveals interplay of aggrecan and aggrecanases in vascular remodeling of stented coronary arteries. *Circulation*. 2018;137:166–183. doi: 10.1161/CIRCULATIONAHA.116.023381.
- Dupuis LE, McCulloch DR, McGarity JD, Bahan A, Wessels A, Weber D, Diminich AM, Nelson CM, Apte SS, Kern CB. Altered versican cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease. *Dev Biol*. 2011;357:152–164. doi: 10.1016/j.ydbio.2011.06.041.
- Davis FM, Rateri DL, Balakrishnan A, Howatt DA, Strickland DK, Muratoglu SC, Haggerty CM, Fornwalt BK, Cassis LA, Daugherty A. Smooth muscle cell deletion of low-density lipoprotein receptor-related protein 1 augments angiotensin II-induced superior mesenteric arterial and ascending aortic aneurysms. *Arterioscler Thromb Vasc Biol*. 2015;35:155–162. doi: 10.1161/ATVBAHA.114.304683.
- Barallobre-Barreiro J, Oklu R, Lynch M, Fava M, Baig F, Yin X, Barwari T, Potier DN, Albadawi H, Jahangiri M, Porter KE, Watkins MT, Misra S, Stoughton J, Mayr M. Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins. *Cardiovasc Res*. 2016;110:419–430. doi: 10.1093/cvr/cvv075.
- Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. *Mol Cell Proteomics*. 2010;9:2048–2062. doi: 10.1074/mcp.M110.001693.
- Barallobre-Barreiro J, Didangelos A, Yin X, Doménech N, Mayr M. A sequential extraction methodology for cardiac extracellular matrix prior to proteomics analysis. *Methods Mol Biol*. 2013;1005:215–223. doi: 10.1007/978-1-62703-386-2\_17.
- Turner NA, Ho S, Warburton P, O'Regan DJ, Porter KE. Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. *J Vasc Surg*. 2007;45:1022–1028. doi: 10.1016/j.jvs.2007.01.061.
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paeppe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol*. 2002;3:1–12.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) method. *Methods*. 2001;25:402–408. doi: 10.1006/meth.2001.1262.
- Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. *Nature*. 2005;434:648–652. doi: 10.1038/nature03417.
- Melching LI, Fisher WD, Lee ER, Mort JS, Roughley PJ. The cleavage of biglycan by aggrecanases. *Osteoarthritis Cartilage*. 2006;14:1147–1154. doi: 10.1016/j.joca.2006.05.014.
- Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, Karamanos NK, Tzanakakis GN. Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. *IUBMB Life*. 2006;58:47–53. doi: 10.1080/15216540500531713.
- Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmermann DR, Lemire JM, Fischer JW, Wight TN, Clowes AW. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. *J Biol Chem*. 2001;276:13372–13378. doi: 10.1074/jbc.M009737200.
- Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. *Curr Opin Cell Biol*. 2002;14:617–623.
- Rodriguez-Manzanique JC, Milchanowski AB, Dufour EK, Leduc R, Iruela-Arispe ML. Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. *J Biol Chem*. 2000;275:33471–33479. doi: 10.1074/jbc.M002599200.
- Theocharis AD, Tsolakis I, Hjerpe A, Karamanos NK. Human abdominal aortic aneurysm is characterized by decreased versican concentration and specific downregulation of versican isoform V(0). *Atherosclerosis*. 2001;154:367–376.
- Gopalakrishnan K, Kumarasamy S, Abdul-Majeed S, Kalinoski AL, Morgan EE, Gohara AF, Nauli SM, Filipiak WE, Saunders TL, Joe B. Targeted disruption of Adamts16 gene in a rat genetic model of hypertension. *Proc Natl Acad Sci USA*. 2012;109:20555–20559. doi: 10.1073/pnas.1211290109.
- Dupuis LE, Osinska H, Weinstein MB, Hinton RB, Kern CB. Insufficient versican cleavage and Smad2 phosphorylation results in bicuspid aortic and pulmonary valves. *J Mol Cell Cardiol*. 2013;60:50–59. doi: 10.1016/j.yjmcc.2013.03.010.
- Foulcer SJ, Nelson CM, Quintero MV, Kuberan B, Larkin J, Dours-Zimmermann MT, Zimmermann DR, Apte SS. Determinants of versican-V1 proteoglycan processing by the metalloproteinase ADAMTS5. *J Biol Chem*. 2014;289:27859–27873. doi: 10.1074/jbc.M114.573287.
- Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. *Proc Natl Acad Sci USA*. 1996;93:9748–9753.
- Kenagy RD, Fischer JW, Davies MG, Berceli SA, Hawkins SM, Wight TN, Clowes AW. Increased plasmin and serine proteinase activity during flow-induced intimal atrophy in baboon PTFE grafts. *Arterioscler Thromb Vasc Biol*. 2002;22:400–404.
- Jönsson-Rylander AC, Nilsson T, Fritsche-Danielson R, Hammarström A, Behrendt M, Andersson JO, Lindgren K, Andersson AK, Wallbrandt P, Rosengren B, Brodin P, Thelin A, Westin A, Hurt-Camejo E, Lee-Sogaard



- CH. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. *Arterioscler Thromb Vasc Biol.* 2005;25:180–185. doi: 10.1161/01.ATV.0000150045.27127.37.
34. McCulloch DR, Nelson CM, Dixon LJ, Silver DL, Wylie JD, Lindner V, Sasaki T, Cooley MA, Argraves WS, Apte SS. ADAMTS metalloproteinases generate active versican fragments that regulate interdigital web regression. *Dev Cell.* 2009;17:687–698. doi: 10.1016/j.devcel.2009.09.008.
  35. Bourd-Boittin K, Bonnier D, Leyme A, Mari B, Tuffery P, Samson M, Ezan F, Baffet G, Theret N. Protease profiling of liver fibrosis reveals the ADAM metalloproteinase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta. *Hepatology.* 2011;54:2173–2184. doi: 10.1002/hep.24598.
  36. Chen X, Lu H, Rateri DL, Cassis LA, Daugherty A. Conundrum of angiotensin II and TGF- $\beta$  interactions in aortic aneurysms. *Curr Opin Pharmacol.* 2013;13:180–185. doi: 10.1016/j.coph.2013.01.002.
  37. Angelov SN, Hu JH, Wei H, Airhart N, Shi M, Dichek DA. TGF- $\beta$  (Transforming Growth Factor- $\beta$ ) signaling protects the thoracic and abdominal aorta from angiotensin II-induced pathology by distinct mechanisms. *Arterioscler Thromb Vasc Biol.* 2017;37:2102–2113. doi: 10.1161/ATVBAHA.117.309401.
  38. Galora S, Saracini C, Pratesi G, Sticchi E, Pulli R, Pratesi C, Abbate R, Giusti B. Association of rs1466535 LRP1 but not rs3019885 SLC30A8 and rs6674171 TDRD10 gene polymorphisms with abdominal aortic aneurysm in Italian patients. *J Vasc Surg.* 2015;61:787–792. doi: 10.1016/j.jvs.2013.10.090.
  39. Chan CY, Chan YC, Cheuk BL, Cheng SW. A pilot study on low-density lipoprotein receptor-related protein-1 in Chinese patients with abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg.* 2013;46:549–556. doi: 10.1016/j.ejvs.2013.08.006.
  40. Lillis AP, Muratoglu SC, Au DT, Migliorini M, Lee MJ, Fried SK, Mikhailenko I, Strickland DK. LDL Receptor-Related Protein-1 (LRP1) regulates cholesterol accumulation in macrophages. *PLoS One.* 2015;10:e0128903. doi: 10.1371/journal.pone.0128903.
  41. Zurhove K, Nakajima C, Herz J, Bock HH, May P. Gamma-secretase limits the inflammatory response through the processing of LRP1. *Sci Signal.* 2008;1:ra15. doi: 10.1126/scisignal.1164263.
  42. Yamamoto K, Troeberg L, Scilabra SD, Pelosi M, Murphy CL, Strickland DK, Nagase H. LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage. *FASEB J.* 2013;27:511–521. doi: 10.1096/fj.12-216671.
  43. Strickland DK, Au DT, Cunfer P, Muratoglu SC. Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity. *Arterioscler Thromb Vasc Biol.* 2014;34:487–498. doi: 10.1161/ATVBAHA.113.301924.
  44. Collins C, Osborne LD, Guilluy C, Chen Z, O'Brien ET III, Reader JS, Burrige K, Superfine R, Tzima E. Haemodynamic and extracellular matrix cues regulate the mechanical phenotype and stiffness of aortic endothelial cells. *Nat Commun.* 2014;5:3984. doi: 10.1038/ncomms4984.
  45. Youssefi P, Gomez A, He T, Anderson L, Bunce N, Sharma R, Figueroa CA, Jahangiri M. Patient-specific computational fluid dynamics-assessment of aortic hemodynamics in a spectrum of aortic valve pathologies. *J Thorac Cardiovasc Surg.* 2017;153:8.e3–20.e3. doi: 10.1016/j.jtcvs.2016.09.040.
  46. Taketani T, Imai Y, Morota T, Maemura K, Morita H, Hayashi D, Yamazaki T, Nagai R, Takamoto S. Altered patterns of gene expression specific to thoracic aortic aneurysms: microarray analysis of surgically resected specimens. *Int Heart J.* 2005;46:265–277.

### Highlights

- Expression of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-5 and the large aggregating proteoglycans is higher in the aortic arch compared with the abdominal aorta.
- AngII (angiotensin II) treatment in Adamts5<sup>Acat</sup> mice is associated with increased dilatation of the ascending aorta.
- Loss of ADAMTS-5 activity induces an accumulation of versican on AngII treatment.
- This is accompanied by an increase in TGF- $\beta$  (transforming growth factor- $\beta$ ) levels and a compensatory upregulation of soluble ADAMTS-1.
- Silencing of LRP1 (low-density lipoprotein-related protein 1) in human aortic smooth muscle cells reduces ADAMTS-5 expression, attenuates ADAMTS-mediated versican cleavage, and increases ADAMTS-1.

FIRST PROOF ONLY

# Arteriosclerosis, Thrombosis, and Vascular Biology



JOURNAL OF THE AMERICAN HEART ASSOCIATION

## **Role of ADAMTS (A Disintegrin and Metalloproteinase With Thrombospondin Motifs)-5 in Aortic Dilatation and Extracellular Matrix Remodeling**

Marika Fava, Javier Barallobre-Barreiro, Ursula Mayr, Ruifang Lu, Athanasios Didangelos,  
Ferheen Baig, Marc Lynch, Norman Catibog, Abhishek Joshi, Temo Barwari, Xiaoke Yin,  
Marjan Jahangiri and Manuel Mayr

*Arterioscler Thromb Vasc Biol.* published online April 5, 2018;  
*Arteriosclerosis, Thrombosis, and Vascular Biology* is published by the American Heart Association, 7272  
Greenville Avenue, Dallas, TX 75231  
Copyright © 2018 American Heart Association, Inc. All rights reserved.  
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the  
World Wide Web at:

<http://atvb.ahajournals.org/content/early/2018/04/04/ATVBAHA.117.310562>  
Free via Open Access

Data Supplement (unedited) at:

<http://atvb.ahajournals.org/content/suppl/2018/04/03/ATVBAHA.117.310562.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Arteriosclerosis, Thrombosis, and Vascular Biology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Arteriosclerosis, Thrombosis, and Vascular Biology* is online at:  
<http://atvb.ahajournals.org/subscriptions/>

## Major Resources Tables

### Animals

| Species/Strain          | Vendor or Source       | Background Strain   | Sex  |
|-------------------------|------------------------|---|------|
| Wildtype mice           | The Jackson Laboratory | C57BL/6J  | male |
| Adamts5 <sup>Δcat</sup> | The Jackson Laboratory | 129P2/OlaHs backcrossed 5 times onto C57BL/6J, one additional backcross was performed to generate the littermates for experiments | male |

### Primary Antibodies

| Target antigen                                      | Vendor or Source | Catalog # | Working concentration           | Lot #       |
|---|------------------|-----------|---------------------------------|-------------|
| Neoepitope on versican generated by ADAMTS cleavage | Abcam            | ab19345   | WB: 1μg/ml<br>IHC: 10μg/ml      | GR314383-6  |
| Full-length versican                                | Millipore        | AB1033    | WB: 0.5μg/ml                    | 2867545     |
| Full-length versican                                | Millipore        | MABT161   | IHC: 2.5μg/ml                   | 2702191     |
| ADAMTS-1  | Thermo Fisher    | 720329    | WB: 2μg/ml                      | SA246704    |
| TGFβ  | Abcam            | ab179695  | WB: 0.512μg/ml                  | GR262076-2  |
| LRP1  | Abcam            | ab92544   | WB: 0.512μg/ml<br>IHC: 4.6μg/ml | GR259330-25 |
| GAPDH   | Sigma            | G8795     | WB: 0.05μg/ml                   | 056M-4856V  |
| Alpha smooth muscle actin                           | Abcam            | Ab21027   | IHC: 4μg/ml                     | GR309074-1  |



## Secondary Antibodies

| Vendor or Source       | Target Species | Catalog #   | Working concentration | Lot #   |
|------------------------|----------------|-------------|-----------------------|---------|
| Jackson ImmunoResearch | Rabbit         | 211-032-171 | WB: 80ng/ml           | 130846  |
| Jackson ImmunoResearch | Mouse          | 115-035-174 | WB: 80ng/ml           | 129518  |
| Invitrogen             | Rabbit         | A21069      | IHC: 2.5 µg/ml        | 1736974 |
| Invitrogen             | Mouse          | A21203      | IHC: 2.5 µg/ml        | 987237  |
| Invitrogen             | Rabbit         | A31573      | IHC: 2.5 µg/ml        | 1900251 |
| Invitrogen             | Goat           | A11055      | IHC: 2.5 µg/ml        | 1081957 |

## Cultured Cells

| Name                               | Vendor or Source   | Sex (F, M, or unknown) |
|------------------------------------|--|------------------------|
| Human aortic SMCs                  | Lonza, US  | Male                   |
| Human internal mammary artery SMCs | Dr. Karen Porter, Leeds Institute of Cardiovascular and Metabolic Medicine | Unknown                |

## Material

| Name                                 | Company            | Catalog Number |
|--------------------------------------|--------------------|----------------|
| <b>1.Chemicals</b>                   |                    |                |
| Cocktail of proteinase inhibitor     | Thermo Scientific  | 51101          |
| Chloroform                           | Sigma-Aldrich      | C2432          |
| Phosho STOP                          | Roche              | 4906837001     |
| Cell Lysis buffer                    | Cell Signalling    | 9803           |
| NuPAGE MOPS SDS Running Buffer (20X) | Life Technologies  | NP0001-02      |
| EDTA                                 | Sigma-Aldrich      | E9884          |
| EGTA                                 | Sigma-Aldrich      | E3889          |
| Ethanol                              | VWR                | 437433T        |
| Formalin                             | Sigma-Aldrich      | HT501128       |
| Guanidine hydrochloride              | Sigma-Aldrich      | G3272          |
| H <sub>2</sub> <sup>18</sup> O       | Taiyo Nippon Salso | FO3-0027       |
| Iodoacetamine                        | Sigma-Aldrich      | A3221          |
| Glycine                              | Sigma-Aldrich      | G8896          |

|   |                   |                 |
|---|-------------------|-----------------|
| Lipofectamine 2000  | Invitrogen        | 12566014        |
| Methanol  | Fisher Chemical   | A4545K          |
| Phosphate-buffered saline (PBS), 10X                      | Lonza             | 51226           |
| Ponceau   | Sigma-Aldrich     | P7170           |
| Quiazol Lysis Reagent                                     | Qiagen            | 4053228006220   |
| Sodium Acetate  | Sigma-Aldrich     | S7545           |
| Sodium Azide  | Sigma-Aldrich     | 08591           |
| Sodium Chloride   | Sigma-Aldrich     | S9888           |
| Sodium dedrcyl sulfate, SDS                               | Sigma-Aldrich     | 466143          |
| Sodium Citrate dihydrate                                  | Sigma-Aldrich     | W302600         |
| Super Script VILO MasterMix                               | Invitrogen        | 11755050        |
| TaqMan Universal PCR Master Mix                           | Applied Biosystem | 4324018         |
| Triethylammonium bicarbonate (TEAB)                       | Sigma-Aldrich     | 11268           |
| Trifluoroacetic acid (TFA)                                | Sigma-Aldrich     | T62200          |
| Thiourea  | Sigma-Aldrich     | T8656           |
| Tris-hydrochloride (Tris-HCl)                             | Sigma-Aldrich     | T3253           |
| Triton X-100  | Sigma-Aldrich     | T8787           |
| Trizma base   | Sigma-Aldrich     | T1503           |
| Tween-20  | Sigma-Aldrich     | P7949           |
| Urea  | Sigma-Aldrich     | U1250           |
| <b>2.Enzymes</b>  |                   |                 |
| $\alpha$ 2-3,6,8,9-neuroaminidase (Sialidase)             | EDM Millipore     | 362280 (KP0012) |
| $\beta$ 1,4-galactosidase                                 | EDM Millipore     | 362280 (KP0004) |
| $\beta$ -N-acetylglucosaminidase                          | EDM Millipore     | 362280 (KP0013) |
| Chrondroitinase ABC                                       | Sigma-Aldrich     | C3667           |
| Endo- $\alpha$ -N-acetylgalactosaminidase (O-glycosidase) | EDM Millipore     | 362280 (KP0011) |
| Heparinase II   | Sigma-Aldrich     | H6512           |
| Keratanase  | Sigma-Aldrich     | G6920           |
| PNGaseF (N-Glycosidase)                                   | EDM Millipore     | 362280 (KP0001) |
| Trypsin   | Thermo Scientific | 90057           |
| <b>3.Reagent kits</b>                                     |                   |                 |
| NuPAGE Novex BisTris Acrylamide gels                      | Thermo Scientific | NP0322PK2       |
| Pierce BCA Protein Assay kit                              | Thermo Scientific | 23227           |
| miRNeasy Mini kit   | Qiagen            | 4053228006220   |

## TaqMan Probes

| Species | Target         | Assay         |
|---------|----------------|---------------|
| Mouse   | <i>Vcan</i>    | Mm01283063_m1 |
| Mouse   | <i>Acan</i>    | Mm00545794_m1 |
| Mouse   | <i>Hapln1</i>  | Mm00488952_m1 |
| Mouse   | <i>Adamts1</i> | Mm01344169_m1 |
| Mouse   | <i>Adamts4</i> | Mm00556068_m1 |
| Mouse   | <i>Adamts5</i> | Mm00478620_m1 |
| Mouse   | <i>Tgfb1</i>   | Mm01178820_m1 |
| Mouse   | <i>Tgfb2</i>   | Mm00436955_m1 |
| Mouse   | <i>Tgfb3</i>   | Mm00436960_m1 |
| Mouse   | <i>Tgfbr1</i>  | Mm00436964_m1 |
| Mouse   | <i>Tgfbr2</i>  | Mm03024091_m1 |
| Mouse   | <i>Tgfbr3</i>  | Mm00803538_m1 |
| Mouse   | <i>Actb</i>    | Mm00607936_s1 |
| Human   | <i>VCAN</i>    | Hs00171642_m1 |
| Human   | <i>GAPDH</i>   | Hs02786624_g1 |
| Human   | <i>ADAMTS1</i> | Hs00199608_m1 |
| Human   | <i>ADAMTS4</i> | Hs00192708_m1 |
| Human   | <i>ADAMTS5</i> | Hs00199841_m1 |
| Human   | <i>LRP1</i>    | Hs00233856_m1 |
| Human   | <i>ACTB</i>    | Hs99999903_m1 |



## **SUPPLEMENTAL MATERIAL**

### **Role of ADAMTS-5 in Aortic Dilatation and Extracellular Matrix Remodeling**

Marika Fava<sup>1,2,3</sup>, Javier Barallobre-Barreiro<sup>1</sup>, Ursula Mayr<sup>1</sup>, Ruifang Lu<sup>1</sup>, Athanasios Didangelos<sup>1</sup>, Ferheen Baig<sup>1</sup>, Marc Lynch<sup>1</sup>, Norman Catibog<sup>1</sup>, Abhishek Joshi<sup>1</sup>, Temo Barwari<sup>1</sup>, Xiaoke Yin<sup>1</sup>, Marjan Jahangiri<sup>2</sup>, Manuel Mayr<sup>1,3</sup>

<sup>1</sup> King's British Heart Foundation Centre, King's College London, London, UK

<sup>2</sup> St George's University of London, NHS Trust, London, UK

<sup>3</sup> Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai,  
New York, US

#### **Address for correspondence:**

Manuel Mayr, MD, PhD, King's British Heart Foundation Centre, King's College London, London, UK Telephone: +44-20 7848 5446, Fax: 020 7848 5298, Email: [manuel.mayr@kcl.ac.uk](mailto:manuel.mayr@kcl.ac.uk)

## ONLINE METHODS

**In vitro metalloprotease digestion assay.** Murine aortic specimens were dissected into smaller pieces and washed 5 times in ice-cold, 1X PBS. The tissue blocks were then mixed with 10 volumes metalloprotease reaction buffer (10mM CaCl<sub>2</sub>, 120mM NaCl and 50mM Trizma base, pH 7.5), which was either used neat (control) or supplemented with different concentrations (50-100pM) of recombinant proteins; murine ADAMTS-1 and murine ADAMTS-5, all purchased from R&D Systems. The samples were incubated for 24hrs at 37°C. Subsequently, the released proteins in the tissue supernatants were deglycosylated. For protein deglycosylation, samples were resuspended in deglycosylation buffer (150mM NaCl, 50mM sodium acetate pH 6.8, 10mM EDTA) for 16hrs at 37°C containing a combination of enzymes for GAG-removal enzymes: chondroitinase ABC (1:100), endo- $\beta$ 1,4-galactosidase (1:500) and heparinase II (1:500). The deglycosylated proteins were separated by gel electrophoresis prior to digestion and LC-MS/MS.

**Gel-LC-MS/MS analysis of aortic supernatants.** Proteins released from aortas on incubation with ADAMTS-1 and ADAMTS-5 were first separated by SDS-PAGE. Sample buffer (100mM Tris pH 6.8, 40% glycerol, 0.2% SDS, 2%  $\beta$ -mercaptoethanol and 0.02% bromophenol blue) was added to the deglycosylated extracts and boiled at 96°C for 10min prior to separation on 4-12% Bis-Tris gradient gels (Life Technologies, Cat No. EC60385BOX). Electrophoresis was performed at 130-170V for 100-120min in 1x NuPage MOPS SDS Running Buffer (Life Technologies). Proteins were silver-stained for visualization and gel lanes were cut into 10 consecutive pieces. All gel bands were subjected to in-gel digestion with trypsin using an Investigator ProGest (Digilab) robotic digestion system. Tryptic peptides were lyophilized, reconstituted with 0.05% TFA in 2% ACN and separated on a nanoflow LC system (ThermoFisher Scientific, Ultimate 3000). Peptides were eluted with a 40-min gradient (10–25% B in 35min, 25–40% B in 5min, 90% B in 10min, and 2%B in 30min where A is 2% ACN, 0.1% formic acid in HPLC H<sub>2</sub>O and B is 90% ACN, 0.1% formic acid in HPLC H<sub>2</sub>O). The column (ThermoFisher Scientific, PepMap C18, 25cm length, 75 $\mu$ m internal diameter, 3 $\mu$ m particle size) was coupled to a nanospray source (Picoview). Spectra were collected from an Orbitrap mass analyzer (LTQ-Orbitrap XL, ThermoFisher Scientific) using full ion scan mode over the mass-to-charge (m/z) range 450–1600. MS/MS was performed on the top six ions in each MS scan using the data-dependent acquisition mode with dynamic exclusion enabled. MS/MS peak lists were generated by extract\_msn.exe and matched to a mouse database (SwissProt\_57.15, 16230 protein entries) using Mascot (version 2.3.01, Matrix Science). Carbamidomethylation of cysteine was chosen as a fixed modification and oxidation of methionine, lysine and proline were chosen as a variable modifications. The mass tolerance was set at 10ppm for the

precursor ions and 0.8Da for fragment ions. Up to two missed cleavages were allowed. Scaffold (version 3.0.08, Proteome Software Inc., Portland, OR) was used to calculate the spectral counts and to validate MS/MS-based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability. Protein identifications were accepted if they could be established at a minimum of 99.0% probability.

**ECM protein extraction.** Diced tissue was weighed (8-12mg) and immediately placed into Eppendorf tubes containing 1 ml of ice-cold PBS supplemented with 1:100 (v:v) of a broad-spectrum protease inhibitor cocktail (Sigma-Aldrich), and 25mM EDTA to ensure inhibition of metalloproteinases. After 5 washes with PBS buffer the diced samples were incubated with a 0.5M NaCl buffer supplemented with 10mM Tris at pH 7.5, 1:100 (v:v) of a proteinase inhibitor cocktail and 25mM EDTA. The volume of the buffer was adjusted to 5:1 (v:w). Samples were mildly vortexed for 2hrs at room temperature (RT) to solubilize loosely bound ECM and ECM-associated proteins, after which the NaCl buffer was collected and frozen for later use. Samples were washed briefly in the PBS buffer, followed by incubation with 0.08% sodium dodecyl sulphate (SDS) supplemented with proteinase inhibitor cocktail and 25mM EDTA (same ratios as for NaCl buffer above). Samples were mildly vortexed for 2hrs at RT to achieve removal of cellular components, taking particular care to ensure a low vortexing speed to avoid mechanical disruption of the ECM. SDS extracts were then collected and frozen for later use. The tissue samples were washed briefly with water. Finally, the samples were incubated in 4M guanidine hydrochloride buffer (GuHCl) supplemented with 50mM sodium acetate at pH 5.8, 1:100 (v:v) of a proteinase inhibitor cocktail and 25mM EDTA. The volume of the buffer was adjusted to 5:1 (v:w) and the incubation was performed for 48hrs at RT. GuHCl destabilises the ionic, disulfide-dependent protein conformations in large aggregating proteoglycans (PGs), small PGs, cell attachment matrix glycoproteins, fibronectins and laminins and basement membrane components. A vigorous vortexing speed was used to enhance mechanical disruption of the ECM components at this stage. GuHCl extracts were collected and protein concentration was measured by spectrophotometry based on the absorbance at 280nm.

**Deglycosylation of ECM extracts.** After extraction, 15µg of protein from GuHCl extracts were incubated with 100% ethanol (1:10 volume ratio) at -20°C overnight. After incubation, proteins were precipitated by centrifugation at 16,000 g for 1h at 4°C. Supernatants were carefully removed and protein pellets were dried using a vacuum centrifuge (ThermoFisher Scientific). Precipitation ensures removal of GuHCl, which would interfere with later steps (i.e. enzymatic digestions). For protein deglycosylation (i.e. removal of glycans attached to proteins), a two-step protocol was pursued. In the first step, samples were resuspended in deglycosylation buffer (0.2mol/L Tris, 0.2mol/L sodium acetate,

0.1mol/L EDTA, 0.05mol/L sodium phosphate, pH 6.8) containing a combination of enzymes for glycosaminoglycan (GAG)-removal (as mentioned above) and three additional enzymes that ensure debranching of sugar residues:  $\alpha$ 2-3,6,8,9-Neuraminidase (from *Arthrobacter ureafaciens*), which cleaves all non-reducing terminal branched and unbranched sialic acids;  $\beta$ 1,4-Galactosidase (from *Streptococcus pneumonia*) releases only  $\beta$ 1,4-linked, non-reducing terminal galactose from complex carbohydrates and glycoproteins;  $\beta$ -N-Acetylglucosaminidase (from *Streptococcus pneumonia*) cleaves all non-reducing terminal  $\beta$ -linked N-acetylglucosamine residues from complex carbohydrates and glycoproteins (all purchased from Merck-Millipore and used at a ratio of 1:200). Endo- $\alpha$ -N-acetylgalactosaminidase (O-glycosidase from *Streptococcus pneumoniae*) was added to ensure removal of O-glycosylation. This enzyme cleaves serine- or threonine-linked unsubstituted Gal $\beta$ 1,3GalNAc. The samples were incubated for 1h at 25°C and 24hrs at 37°C, at 200rpm. Removal of sugar monomers facilitates the later cleavage by PNGase-F. This enzyme cleaves all asparagine-linked oligosaccharides unless  $\alpha$ 1,3-core fucosylated. Importantly, asparagine must be peptide-bonded at both termini. After the first incubation step, water was evaporated from the extracts and substituted for an equal amount of H<sub>2</sub><sup>18</sup>O containing 1:100 PNGase-F (N-glycosidase F). Subsequently, samples were incubated under constant agitation, at 37°C for 48hrs. Deglycosylation in the presence of H<sub>2</sub><sup>18</sup>O, ensures labelling of asparagines with <sup>18</sup>O every time a deglycosylation event takes place. During LC-MS/MS analysis, detection of <sup>18</sup>O in deamidated asparagines is an indirect indicator of the presence of N-glycosylation.

**In-solution digestion and C18 clean-up of ECM extracts.** Deglycosylated GuHCl extracts were denatured by the addition of 9M urea, 3M thiourea (final conc. 6M urea, 2M thiourea), and reduced by the addition of 100mM DTT (final conc. 10mM) followed by incubation at 37°C for 1h, 240rpm. The samples were then cooled down to RT before being alkylated by the addition of 500mM iodoacetamide (final conc. 50mM) followed by incubation in the dark for 1h. Pre-chilled (-20°C) acetone (8x volume) was used to precipitate the samples overnight at -20°C. Samples were centrifuged at 14,000 g for 25min at 4°C and the supernatant subsequently discarded. Protein pellets were dried using a speed vac (Thermo Scientific, Savant SPD131DDA), re-suspended in 0.1M TEAB buffer, pH 8.2, containing trypsin (Cat No. 90057, Thermo Scientific; 1:50, trypsin:protein) and digested overnight at 37°C, 240rpm. The digestion was stopped by acidification of the samples with 10% TFA (final concentration 1% TFA). Peptide samples were purified using a 96-well C18 spin plate (Harvard Apparatus). The resin was activated using 200 $\mu$ l methanol and centrifuged at 1,000 g for 1min. Wash steps included 200 $\mu$ l of 80% ACN, 0.1% TFA in H<sub>2</sub>O, and three equilibration steps using 200 $\mu$ l of 1% ACN, 0.1% TFA in H<sub>2</sub>O with centrifugation (1,000 g for 1min) after each step. Samples were loaded onto the resin and centrifuged at 2,000 g for



1min; the flow-through was reloaded onto the resin a second time and centrifugation repeated. The resin was then washed three times with 200  $\mu$ l 1% ACN, 0.1% TFA in H<sub>2</sub>O (centrifugation at 1,500 g for 1min). Finally, the samples were eluted with 170 $\mu$ l of 50% acetonitrile, 0.1% TFA in H<sub>2</sub>O (centrifugation at 1,500 g for 1min); this step was repeated, combining the collected eluate. The eluates were dried using a speed vac (Thermo Scientific, Savant SPD131DDA) and re-suspended in 0.05% TFA in 2% ACN for LC-MS/MS analysis.

**Discovery proteomics in ECM extracts.** The resuspended peptide samples were separated on a nanoflow LC system (UltiMate 3000 RSLC nano). Samples were injected onto a nano-trap column (Acclaim® PepMap100 C18 Trap, 5mm x 300 $\mu$ m, 5 $\mu$ m, 100Å), at a flow rate of 25 $\mu$ L/min for 3min, using 0.1% FA in H<sub>2</sub>O. The following nano LC gradient was used to separate the peptides at 0.3 $\mu$ L/min: 0–10min, 4–10% B; 10–75min, 10–30% B; 75–80min, 30–40% B; 80–85min, 40–99%B, 85–89.8min 99%B, 89.8–90min 99–4%B, 90–120min 4% B, where A = 0.1% FA in H<sub>2</sub>O, B = 80% ACN, 0.1% FA in H<sub>2</sub>O. The nano column (Acclaim PepMap100 C18, 50 cm x 75  $\mu$ m, 3  $\mu$ m, 100 Å) was kept at 40°C and coupled to a nanospray source (Picoview, New Objective, US). Spectra were collected from a Q Exactive HF (Thermo Fisher Scientific) using full MS mode (resolution of 60,000 at 200m/z) over the mass-to-charge (m/z) range 350–1600. Data-dependent MS/MS scan was performed using the top 15 ions in each full MS scan (resolution of 15,000 at 200m/z) with dynamic exclusion enabled. Proteome Discoverer (version 2.1.0.81, Thermo Scientific) was used to search raw data files against the mouse data-base (UniProtKB/Swiss-Prot version 2016\_02, 16683 protein entries) using Mascot (version 2.3.01, Matrix Science). The mass tolerance was set at 10ppm for precursor ions and 20mmu for fragment ions. Trypsin was used as the enzyme with up to two missed cleavages being allowed. Carbamidomethylation of cysteine was chosen as a fixed modification; oxidation of methionine, lysine and proline, and deamidation of asparagine in the presence of <sup>18</sup>O water were chosen as variable modifications. Scaffold (version 4.7.3, Proteome Software Inc., Portland, OR) was used to validate MS/MS-based peptide and protein identifications with the following filters; a peptide probability of greater than 95.0% (as specified by the Peptide Prophet algorithm), a protein probability of greater than 99.0%, and at least two independent peptides per protein. The normalized total ion current (TIC) was used for quantification.

**Targeted proteomics in ECM extracts.** A Parallel Reaction Monitoring (PRM) method was developed using Skyline software (version 3.6, MacCoss Lab Software). Data from the discovery proteomics analysis were used to select proteotypic peptides of ECM and related proteins. Precursor ions for proteins of interest that were not detected in the untargeted analysis were predicted *in silico* using SRM Atlas. Skyline was used to optimize

retention times. Proteotypic peptides were scheduled using the retention time obtained from test experiments with the same LC configuration and eluting gradient; retention time windows were set at  $\pm$  4min. The same LC and Q Exactive HF system was used as for untargeted analysis but with a 220min LC gradient. After trapping, at a flow rate of 25 $\mu$ L/min for 3min, using 0.1% FA in H<sub>2</sub>O, the following nano-LC gradient was applied at 0.3 $\mu$ L/min: 0–20min, 4–8% B; 20–200min, 8–25% B; 200–210min, 25–40% B; 210–215min, 40–99% B, 215–219.8min, 99% B, 219.8–220min, 99–4% B, 220–250min 4% B, where A=0.1% FA in H<sub>2</sub>O, B=80% ACN, 0.1%FA in H<sub>2</sub>O. Spectra were collected on a Q Exactive HF (ThermoFisher Scientific) in PRM mode (MS/MS resolution of 30,000 at 200m/z). An isolation window of 2.0 m/z, automatic gain control (AGC) values of 2E5 and a maximum injection time of 60ms were used. Fragmentation was performed with a normalized collision energy of 28. MS/MS scans were acquired with a first fixed mass of 110.0m/z. The identity of a specific peptide was confirmed by the presence of multiple fragment ions at the same retention time. The inclusion list is shown in **Supplemental Table III**.

**Western blot.** Aliquots from GuHCl and total protein extracts were mixed with protein loading buffer and denatured at 98°C for 5-10min before being briefly centrifuged. Protein samples were separated on 4-12% Bis-Tris gradient gels at 130-170V for 100-120min in 1x NuPage MOPs SDS Running Buffer. Subsequently, the samples were transferred to nitrocellulose membranes in ice-cold transfer buffer (25 mM Tris-Base and 200mM Glycine in 20% methanol). Ponceau S red staining was used to ensure efficient transfer and equal loading. Next, membranes were blocked in 5% milk in PBS with 0.1% Tween-20 (PBST) for 1h on a shaker at RT. After a brief wash in PBST, they were incubated overnight with primary antibody solution. Please see the Major Resources Table in the Supplemental Material. The following day, after three washes in PBST (15min each), the membranes were incubated for 1h at RT with the HRP-conjugated secondary antibody diluted in 5% milk in PBST, according to the source of the primary antibody. The membranes were then washed three times in PBST for 15min and developed using ECL western blotting detection reagent using either X-ray films (FUJIFILM) or Chemidoc Touch, Imaging System (BIORAD). Immunoblots were quantified by densitometry using Image-J software.

**RNA isolation.** RNA extraction was performed using the miRNeasy Mini Kit (Qiagen) following the manufacturers' protocol. For aortic tissue, samples were diced using a scalpel, incubated in 700 $\mu$ L of Qiazol Lysis Reagent and homogenised using FastPrep ceramic lysis beads (Matrix D, MPBio). Cells were washed twice in cold sterile PBS and lysed in 700 $\mu$ L of Qiazol Lysis Reagent. Samples were subsequently incubated at RT for 5min, and then vortexed with 140 $\mu$ L of chloroform. The lysate was then incubated for a further 5min at RT before being centrifuged for 15min at 12,000 g, at 4°C. 280 $\mu$ L of the upper aqueous phase

were transferred to a new tube, mixed with 1.5 volumes of 100% ethanol and transferred into a miRNeasy mini column. The remaining centrifugation steps were carried out at RT. The column was centrifuged for 1min at 12,000 g and the flow through was discarded, next 700µl of RWT buffer was added to the column, centrifuged for 1min at 12,000 g and the flow through was discarded. Next, 500µl of RPE buffer were added to the column before a further centrifugation step for 1min at 12,000 g. The flow through was discarded and a further 500µl of RPE buffer were added to the column before it was centrifuged at 12,000 g for 2min. The columns were transferred to clean collection tubes and centrifuged at 15,000 g for 1min, before being transferred to a new tube. The RNA was eluted with 30µl of RNase-free water, by centrifugation at 10,000 g for 1min. RNA concentration (Abs 260nm) and purity (260/280) were measured in 1µl using spectrophotometry (NanoDrop ND-1000, ThermoScientific). Integrity of RNA was evaluated using Agilent Bioanalyser System. RNA quality was considered acceptable if the RNA integrity number (RIN) was above 7.

**Reverse transcription (RT) and quantitative real-time PCR (qPCR).** The RNA was reverse-transcribed using random hexamers with SuperScript VILO MasterMix (Invitrogen) according to manufacturers' protocol, with sample preparation being performed on a StarChill PCR rack to maintain low temperature. RNA concentration of samples was adjusted to contain equal amounts of RNA (250-500ng) in 8µl using RNase-free water. No DNase treatment was performed. The reverse transcription reaction was set up by mixing the 8µl of RNA with 2µl of SuperScript VILO MasterMix. RT reaction was performed in a Veriti thermal cycler (Applied Biosystems) with the following protocol: incubation at 25°C for 10min followed by 2hrs incubation at 42°C. the reaction was terminated by incubation at 85°C for 5min. Samples were kept at 4°C for immediate use in the qPCR reaction or stored at -20°C.

The RT product was diluted 1:15 to 1:25 using RNase-free water. TaqMan assays using hydrolysis probes (Major Resources Tables) were used for quantitative PCR (qPCR). 2.25µl of diluted RT product were combined with 2.5µl of TaqMan Universal PCR Master Mix, no AmpErase UNG (Applied Biosystems), 0.25µl of TaqMan assays on a MicroAmp Optical 384-well reaction plate, using a Bravo Liquid Handling Platform (Agilent). qPCR reaction was performed in a ViiA 7 Real-Time PCR System (Applied Biosystems), set to run as follows: incubation at 95°C for 10min, followed by 40 cycles of 95°C for 15sec and 60°C for 1min. Data was analysed using ViiA 7 software (Applied Biosystems). A minimum of two reference genes was used throughout the study and stability of RNA isolation, RT and qPCR was determined by variability of and correlation between reference genes. Relative amounts of the targets were calculated using the  $2^{-\Delta\Delta Cq}$  method,<sup>17</sup> with statistical analysis performed on  $\Delta Cq$  values.

**Supplemental Table I.** Extracellular proteins released from mouse aortas on incubation with ADAMTS-1 or ADAMTS-5.

| Identified Proteins  | Uniprot Accession | M <sub>r</sub> (kDa) | Control   | ADAMTS-1   | ADAMTS-5   | P-value      |
|--|-------------------|----------------------|-----------|------------|------------|--------------|
| <b>ADAMTS-1</b>  | P97857            | 106                  | 0±0       | 42.5±0.4   | 0±0        | <b>0.036</b> |
| <b>ADAMTS-5</b>  | Q9R001            | 102                  | 0±0       | 0±0        | 15.9±8.4   | <b>0.036</b> |
| Adipocyte enhancer-binding protein 1                         | Q640N1            | 128                  | 24.0±5.4  | 23.4±1.9   | 27.2±0.8   | 0.339        |
| Adiponectin  | Q60994            | 27                   | 2.4±2.2   | 5.5±2.2    | 0.6±1.1    | 0.079        |
| Aggrecan   | Q61282            | 222                  | 0±0       | 0±0        | 0.6±1.1    | >0.999       |
| Agrin  | A2ASQ1            | 208                  | 0±0       | 3.3±1.5    | 3.2±3.0    | 0.186        |
| Alpha-2-HS-glycoprotein                                      | P29699            | 37                   | 4.8±2.3   | 3.6±0.6    | 2.6±2.2    | 0.543        |
| Annexin A2   | P07356            | 39                   | 7.7±6.8   | 12.0±3.0   | 17.5±4.5   | 0.100        |
| Apolipoprotein A-I   | Q00623            | 31                   | 0±0       | 1.0±1.7    | 0±0        | >0.999       |
| Apolipoprotein A-IV  | P06728            | 45                   | 0.8±1.4   | 0±0        | 0±0        | >0.999       |
| Beta-2-glycoprotein 1  | Q01339            | 39                   | 10.7±2.8  | 6.5±1.5    | 6.5±0.6    | 0.071        |
| Biglycan   | P28653            | 42                   | 6.0±3.4   | 6.5±1.5    | 7.1±2.9    | 0.929        |
| Cell surface glycoprotein MUC18                              | Q8R2Y2            | 72                   | 7.7±1.8   | 9.7±1.0    | 8.1±1.5    | 0.296        |
| Chondroitin sulfate proteoglycan 4                           | Q8VHY0            | 252                  | 46.5±12.1 | 34.4±2.1   | 40.4±4.8   | 0.132        |
| Clusterin  | Q06890            | 52                   | 0±0       | 1.6±2.8    | 0±0        | >0.999       |
| Collagen alpha-1(I)  | P11087            | 138                  | 3.3±1.2   | 3.2±1.1    | 2.6±2.5    | 0.132        |
| <b>Collagen alpha-1(III)</b>                                 | P08121            | 139                  | 7.9±1.7   | 8.8±0.9    | 5.5±0.5    | <b>0.050</b> |
| Collagen alpha-1(VI)   | Q04857            | 108                  | 83.1±6.3  | 84.1±4.9   | 89.9±5.8   | 0.361        |
| Collagen alpha-1(XII)  | Q60847            | 340                  | 7.6±4.0   | 15.9±1.1   | 15.9±5.7   | 0.100        |
| Collagen alpha-1(XIV)  | Q80X19            | 193                  | 68.2±19.5 | 78.6±3.6   | 70.5±7.8   | 0.511        |
| Collagen alpha-1(XV)   | O35206            | 140                  | 42.7±5.7  | 43.5±3.5   | 37.5±4.0   | 0.339        |
| Collagen alpha-1(XVIII)                                      | P39061            | 182                  | 37.2±3.7  | 38.0±2.4   | 36.5±5.3   | 0.829        |
| Collagen alpha-2(I)  | Q01149            | 130                  | 3.0±2.6   | 3.9±1.0    | 3.9±0      | 0.929        |
| Collagen alpha-2(IV)   | P08122            | 167                  | 1.2±2.1   | 2.0±3.4    | 1.6±2.8    | >0.999       |
| Collagen alpha-2(VI)   | Q02788            | 110                  | 35.6±3.4  | 47.1±5.9   | 47.5±6.3   | 0.071        |
| <b>Collagen alpha-6(VI)</b>                                  | Q8C6K9            | 246                  | 18.2±2.2  | 30.2±4.7   | 34.9±5.2   | <b>0.025</b> |
| Decorin  | P28654            | 40                   | 1.7±1.5   | 2.3±2.0    | 2.9±2.9    | 0.593        |
| Extracellular superoxide dismutase [Cu-Zn]                   | O09164            | 27                   | 38.5±11.3 | 43.5±6     | 44.3±2.4   | 0.829        |
| Fibromodulin   | P50608            | 43                   | 0±0       | 2.0±3.4    | 1.9±1.9    | 0.679        |
| <b>Fibronectin</b>   | P11276            | 272                  | 48.0±4.4  | 56.2±10.9  | 89.6±10.7  | <b>0.025</b> |
| Fibulin-2  | P37889            | 132                  | 1.6±2.8   | 1.6±2.8    | 7.4±7.7    | 0.071        |
| Fibulin-5  | Q9WVH9            | 50                   | 32.5±3.5  | 32.4±4.7   | 33.7±2.2   | 0.879        |
| Integrin alpha-5   | P11688            | 115                  | 0±0       | 0±0        | 1.0±1.7    | >0.999       |
| <b>Integrin alpha-IIb</b>                                    | Q9QUM0            | 113                  | 19.4±4.1  | 1.6±2.8    | 0±0        | <b>0.036</b> |
| <b>Integrin beta-1</b>                                       | P09055            | 88                   | 5.0±0.9   | 2.0±2.0    | 0.6±1.1    | <b>0.025</b> |
| <b>Integrin beta-3</b>                                       | O54890            | 87                   | 7.9±1.1   | 0.7±1.1    | 0±0        | <b>0.036</b> |
| Laminin subunit alpha-2                                      | Q60675            | 343                  | 1.8±3.1   | 4.9±1.7    | 6.5±2.1    | 0.132        |
| Laminin subunit alpha-4                                      | P97927            | 202                  | 1.4±2.5   | 3.6±3.1    | 2.6±2.2    | 0.529        |
| Laminin subunit beta-1                                       | P02469            | 197                  | 0.7±1.2   | 4.9±2.5    | 5.2±3.4    | 0.132        |
| Laminin subunit beta-2                                       | Q61292            | 196                  | 23.8±2.7  | 24.4±1.9   | 19.7±2.5   | 0.139        |
| Laminin subunit gamma-1                                      | P02468            | 177                  | 25.0±5.0  | 20.4±4.3   | 24.6±1.6   | 0.339        |
| Latent-TGFβ-binding protein 1                                | Q8CG19            | 187                  | 1.7±1.5   | 1.0±1.7    | 4.9±1.0    | 0.068        |
| Latent-TGFβ-binding protein 4                                | Q8K4G1            | 179                  | 120.8±21. | 123.7±10.1 | 130.9±17.7 | 0.629        |
| <b>Lumican</b>   | P51885            | 38                   | 14.7±2.3  | 21.1±2.6   | 17.5±2.6   | <b>0.025</b> |
| Microfibril-associated glycoprotein 4                        | Q9D1H9            | 29                   | 1.6±2.8   | 0±0        | 0±0        | >0.999       |
| <b>Mimecan</b>   | Q62000            | 34                   | 7.0±0.8   | 10.0±3.8   | 10.7±1.7   | <b>0.050</b> |
| Periostin  | Q62009            | 93                   | 28.6±5.6  | 27.3±2.4   | 26.9±1.6   | 0.993        |
| Perlecan   | Q05793            | 398                  | 126.5±13  | 131.5±1.1  | 129.4±7.2  | 0.721        |
| Prolargin  | Q9JK53            | 43                   | 2.2±3.8   | 7.2±3.2    | 5.8±4.2    | 0.357        |
| <b>Prolow-density lipoprotein receptor-related protein 1</b> | Q91ZX7            | 505                  | 4.6±1.4   | 6.2±1.1    | 8.1±0.6    | <b>0.011</b> |
| Tenascin   | Q80YX1            | 232                  | 1.1±1.8   | 2.9±1.0    | 1.3±2.3    | 0.400        |
| TGFβ-induced protein ig-h3                                   | P82198            | 75                   | 5.2±1.2   | 9.1±0.6    | 8.4±3.1    | 0.139        |
| <b>Thrombospondin-1</b>                                      | P35441            | 130                  | 17.5±2.9  | 13.6±1.9   | 7.4±3.7    | <b>0.011</b> |
| <b>Versican</b>  | Q62059            | 367                  | 0±0       | 5.2±0.6    | 4.5±1.1    | <b>0.025</b> |
| vWF A domain-containing protein 5A                           | Q99KC8            | 87                   | 5.6±1.2   | 9.4±1.9    | 11±3.9     | 0.071        |

Values are normalised Total Spectral counts (Av±SD). P-values for changes among the different groups (n=3) were identified by Kruskal-Wallis test. Results in bold indicate  $P < 0.05$ . Values are average (Av) normalised total spectra ± standard deviation (SD). Control: incubation in buffer only.



**Supplemental Table II.** ECM-related proteins in murine aortas of AngII-treated Adamts5<sup>+/+</sup> and Adamts5<sup>Δcat</sup> mice.

| Identified proteins                        | Uniprot accession | Mr (kDa) | Total spectra | Unique spectra | Unique peptides | Sequence coverage | Fold change | P-value |
|--|-------------------|----------|---------------|----------------|-----------------|-------------------|-------------|---------|
| Adiponectin                                | ADIPO             | 27       | 14            | 4              | 4               | 9.7               | NA          | NA      |
| Aggrecan core protein                      | PGCA              | 222      | 328           | 54             | 34              | 17.0              | 1.10        | 0.662   |
| Agrin                                      | AGRIN             | 208      | 87            | 21             | 19              | 10.6              | 1.15        | 0.792   |
| Alpha-2-HS-glycoprotein                    | FETUA             | 37       | 15            | 10             | 8               | 31.9              | NA          | NA      |
| Amyloid beta A4 protein                    | A4                | 87       | 74            | 20             | 17              | 20.3              | 0.60        | 0.429   |
| Annexin A2                                 | ANXA2             | 39       | 129           | 25             | 19              | 47.2              | 1.53        | 0.126   |
| Apolipoprotein A-I                         | APOA1             | 31       | 91            | 17             | 12              | 42.4              | 1.60        | 0.247   |
| Apolipoprotein A-IV                        | APOA4             | 45       | 31            | 10             | 10              | 19.2              | 1.35        | 0.794   |
| Apolipoprotein C-III                       | APOC3             | 11       | 7             | 5              | 3               | 50.5              | NA          | NA      |
| Apolipoprotein E                           | APOE              | 36       | 56            | 19             | 13              | 43.4              | 3.32        | 0.420   |
| Asporin                                    | ASPN              | 43       | 292           | 44             | 22              | 55.8              | 1.05        | 0.571   |
| Basal cell adhesion molecule               | BCAM              | 68       | 157           | 30             | 23              | 35.7              | 0.69        | 0.082   |
| Beta-2-glycoprotein 1                      | APOH              | 39       | 118           | 23             | 17              | 60.6              | 2.06        | 0.082   |
| Biglycan                                   | PGS1              | 42       | 845           | 90             | 31              | 66.9              | 1.05        | 0.792   |
| Cadherin-13                                | CAD13             | 78       | 43            | 6              | 6               | 9.5               | 1.20        | 0.662   |
| Cathepsin B                                | CATB              | 37       | 9             | 3              | 3               | 9.1               | NA          | NA      |
| Cathepsin D                                | CATD              | 45       | 50            | 9              | 6               | 23.9              | 1.34        | 0.429   |
| Chondroitin sulfate proteoglycan 4         | CSPG4             | 252      | 18            | 9              | 9               | 5.2               | NA          | NA      |
| Chymase                                    | CMA1              | 28       | 53            | 9              | 8               | 33.6              | 1.02        | 0.792   |
| Clusterin                                  | CLUS              | 52       | 167           | 30             | 21              | 49.1              | 1.57        | 0.266   |
| Collagen alpha-1(I) chain                  | CO1A1             | 138      | 4768          | 269            | 114             | 76.0              | 0.87        | 0.355   |
| Collagen alpha-1(II) chain                 | CO2A1             | 142      | 125           | 13             | 10              | 10.1              | 0.93        | 0.662   |
| Collagen alpha-1(III) chain                | CO3A1             | 139      | 756           | 114            | 62              | 52.8              | 0.54        | 0.931   |
| Collagen alpha-1(IV) chain                 | CO4A1             | 161      | 135           | 28             | 14              | 10.8              | 0.86        | 0.792   |
| Collagen alpha-1(V) chain                  | CO5A1             | 184      | 248           | 31             | 24              | 13.8              | 0.73        | 0.247   |
| Collagen alpha-1(VI) chain                 | CO6A1             | 108      | 247           | 53             | 35              | 33.4              | 0.66        | 0.178   |
| Collagen alpha-1(XI) chain                 | COBA1             | 181      | 25            | 7              | 6               | 4.2               | NA          | NA      |
| Collagen alpha-1(XII) chain                | COCA1             | 340      | 37            | 23             | 22              | 9.5               | 3.80        | 0.446   |
| Collagen alpha-1(XIII) chain               | CODA1             | 73       | 2             | 2              | 2               | 8.7               | NA          | NA      |
| Collagen alpha-1(XIV) chain                | COEA1             | 193      | 55            | 19             | 18              | 8.9               | 1.13        | 0.922   |
| Collagen alpha-1(XV) chain                 | COFA1             | 140      | 162           | 25             | 17              | 14.9              | 1.08        | 0.931   |
| Collagen alpha-1(XVIII) chain              | COIA1             | 182      | 427           | 56             | 35              | 23.7              | 0.94        | 0.537   |
| Collagen alpha-2(I) chain                  | CO1A2             | 130      | 2855          | 210            | 91              | 71.6              | 0.96        | 0.792   |
| Collagen alpha-2(IV) chain                 | CO4A2             | 167      | 80            | 19             | 14              | 9.0               | 0.83        | 0.792   |
| Collagen alpha-2(V) chain                  | CO5A2             | 145      | 457           | 62             | 43              | 41.3              | 1.33        | 0.178   |
| Collagen alpha-2(VI) chain                 | CO6A2             | 110      | 220           | 48             | 27              | 34.8              | 0.51        | 0.139   |
| Collagen alpha-3(IV) chain                 | CO4A3             | 162      | 2             | 2              | 2               | 1.9               | NA          | NA      |
| Collagen alpha-6(VI) chain                 | CO6A6             | 246      | 65            | 20             | 20              | 10.6              | 0.26        | 0.121   |
| Connective tissue growth factor            | CTGF              | 38       | 73            | 17             | 15              | 44.3              | 0.81        | 0.623   |
| Decorin                                    | PGS2              | 40       | 721           | 84             | 34              | 73.2              | 1.21        | 0.126   |
| Dermatopontin                              | DERM              | 24       | 125           | 21             | 10              | 53.7              | 1.11        | 0.329   |
| Dystroglycan                               | DAG1              | 97       | 26            | 7              | 5               | 4.8               | 1.61        | 0.305   |
| Elastin                                    | ELN               | 72       | 67            | 12             | 10              | 21.4              | 0.63        | 0.126   |
| EMILIN-1                                   | EMIL1             | 108      | 21            | 9              | 9               | 5.2               | 0.86        | 0.794   |
| Extracellular matrix protein 1             | ECM1              | 63       | 21            | 6              | 6               | 10.0              | 0.96        | 0.100   |
| Extracellular superoxide dismutase         | SODE              | 27       | 268           | 40             | 16              | 74.1              | 1.04        | 0.931   |
| Fibrillin-1                                | FBN1              | 312      | 62            | 18             | 17              | 8.1               | 0.69        | 0.881   |
| Fibromodulin                               | FMOD              | 43       | 83            | 17             | 10              | 36.2              | 1.14        | 0.792   |
| Fibronectin                                | FINC              | 273      | 1424          | 244            | 124             | 58.6              | 1.00        | 0.792   |
| Fibulin-2                                  | FBLN2             | 132      | 2             | 2              | 2               | 2.5               | NA          | NA      |
| Fibulin-5                                  | FBLN5             | 50       | 151           | 21             | 15              | 38.8              | 0.76        | 0.429   |
| Galectin-1                                 | LEG1              | 15       | 121           | 17             | 9               | 48.1              | 1.38        | 0.056   |
| Galectin-3                                 | LEG3              | 28       | 68            | 11             | 7               | 31.1              | 1.56        | 0.178   |
| Galectin-3-binding protein                 | LG3BP             | 64       | 5             | 5              | 5               | 14.2              | NA          | NA      |
| Hyaluronan and proteoglycan link protein 1 | HPLN1             | 40       | 24            | 9              | 8               | 22.2              | NA          | NA      |
| Kininogen-1                                | KNG1              | 73       | 4             | 4              | 4               | 11.5              | NA          | NA      |
| Lactadherin                                | MFGM              | 51       | 372           | 53             | 27              | 60.9              | 1.03        | >0.99   |
| Laminin subunit alpha-2                    | LAMA2             | 344      | 14            | 8              | 8               | 2.1               | NA          | NA      |
| Laminin subunit alpha-4                    | LAMA4             | 202      | 83            | 18             | 18              | 9.6               | 1.09        | 0.931   |


|   |              |            |            |           |           |             |             |              |
|---|--------------|------------|------------|-----------|-----------|-------------|-------------|--------------|
| Laminin subunit alpha-5                               | LAMA5        | 404        | 77         | 20        | 19        | 6.0         | 1.01        | 0.792        |
| Laminin subunit beta-1                                | LAMB1        | 197        | 5          | 5         | 5         | 2.5         | NA          | NA           |
| Laminin subunit beta-2                                | LAMB2        | 197        | 224        | 46        | 37        | 20.0        | 1.06        | 0.792        |
| Laminin subunit gamma-1                               | LAMC1        | 177        | 201        | 41        | 35        | 20.8        | 1.03        | 0.931        |
| Latent-TGF $\beta$ -binding protein 1                 | LTBP1        | 187        | 63         | 12        | 11        | 6.4         | 0.96        | 0.792        |
| Latent-TGF $\beta$ -binding protein 2                 | LTBP2        | 196        | 16         | 7         | 7         | 4.6         | NA          | NA           |
| Latent-TGF $\beta$ -binding protein 4                 | LTBP4        | 179        | 247        | 49        | 37        | 21.6        | 0.86        | 0.537        |
| Lumican   | LUM          | 38         | 575        | 66        | 28        | 72.8        | 1.38        | 0.056        |
| Matrix Gla protein                                    | MGP          | 12         | 6          | 3         | 2         | 23.1        | NA          | NA           |
| Metalloproteinase inhibitor 3                         | TIMP3        | 24         | 20         | 5         | 5         | 20.9        | 1.27        | 0.790        |
| Microfibril-associated glycoprotein 4                 | MFAP4        | 29         | 112        | 18        | 9         | 43.6        | 1.17        | 0.429        |
| <b>Microfibrillar-associated protein 5</b>            | <b>MFAP5</b> | <b>19</b>  | <b>112</b> | <b>13</b> | <b>6</b>  | <b>37.8</b> | <b>1.78</b> | <b>0.030</b> |
| Mimecan   | MIME         | 34         | 494        | 54        | 27        | 58.7        | 1.26        | 0.247        |
| Nephronectin  | NPNT         | 61         | 137        | 22        | 15        | 28.7        | 0.69        | 0.052        |
| Nidogen-1   | NID1         | 137        | 285        | 54        | 41        | 32.4        | 1.12        | 0.329        |
| Nidogen-2   | NID2         | 154        | 160        | 37        | 27        | 16.5        | 1.02        | 0.972        |
| Periostin   | POSTN        | 93         | 503        | 94        | 53        | 51.3        | 0.75        | 0.429        |
| Perlecan  | PGBM         | 398        | 1810       | 271       | 148       | 46.4        | 0.91        | 0.537        |
| Prolargin   | PRELP        | 43         | 455        | 51        | 26        | 77.8        | 1.33        | 0.178        |
| Prolow-density lipoprotein receptor-related protein 1 | LRP1         | 505        | 28         | 13        | 12        | 2.55        | NA          | NA           |
| Prosaposin  | SAP          | 61         | 39         | 9         | 7         | 19.2        | 1.54        | 0.429        |
| Protein S100-A10                                      | S10AA        | 11         | 38         | 7         | 5         | 52.6        | 2.30        | 0.080        |
| Protein S100-A11                                      | S10AB        | 11         | 9          | 3         | 2         | 27.6        | NA          | NA           |
| Protein S100-A4                                       | S10A4        | 12         | 8          | 5         | 3         | 20.8        | NA          | NA           |
| Sclerostin  | SOST         | 23         | 27         | 5         | 4         | 18.0        | 0.73        | 0.329        |
| Serine protease HTRA1                                 | HTRA1        | 51         | 308        | 41        | 24        | 49.2        | 0.79        | 0.792        |
| Serine protease HTRA3                                 | HTRA3        | 49         | 35         | 12        | 10        | 20.9        | 1.09        | >0.99        |
| SPARC   | SPRC         | 34         | 17         | 5         | 5         | 12.6        | 0.65        | 0.550        |
| Tenascin  | TENA         | 232        | 277        | 70        | 59        | 27.2        | 0.94        | 0.792        |
| TGF- $\beta$ 1  | TGFB1        | 44         | 9          | 9         | 9         | 37.9        | NA          | NA           |
| TGF- $\beta$ 2  | TGFB2        | 48         | 19         | 4         | 3         | 12.1        | 2.10        | 0.268        |
| TGF- $\beta$ 3  | TGFB3        | 47         | 4          | 2         | 2         | 6.1         | NA          | NA           |
| TGF $\beta$ -induced protein ig-h3                    | BGH3         | 75         | 91         | 24        | 18        | 31.0        | 0.66        | 0.429        |
| Thrombospondin type-1 domain-containing protein 4     | THSD4        | 113        | 87         | 15        | 13        | 13.7        | 0.85        | 0.662        |
| Thrombospondin-1                                      | TSP1         | 130        | 23         | 10        | 10        | 10.9        | 2.93        | >0.99        |
| Tubulointerstitial nephritis antigen-like             | TINAL        | 53         | 264        | 49        | 27        | 66.5        | 1.02        | 0.931        |
| Vascular cell adhesion protein 1                      | VCAM1        | 81         | 3          | 3         | 3         | 5.4         | NA          | NA           |
| <b>Versican</b>                                       | <b>CSPG2</b> | <b>367</b> | <b>112</b> | <b>20</b> | <b>14</b> | <b>4.6</b>  | <b>2.19</b> | <b>0.009</b> |
| Vitronectin   | VTNC         | 55         | 139        | 24        | 15        | 37.2        | 1.90        | >0.99        |
| von Willebrand factor A domain-containing protein 1   | VWA1         | 45         | 59         | 13        | 11        | 38.1        | 0.71        | 0.755        |

Number of samples: WT n=6, KO: n=5 *P* values were derived from unpaired Mann Whitney tests and significant changes ( $p < 0.05$ ) are highlighted in bold. NA denotes "not applicable" (note that every time protein expression in more than 3 samples from both groups was undetectable, the test was not performed). Sequence coverage is given in %.

**Supplemental Table III.** PRM parameter used for targeted MS analysis of unique peptides from versican.


| Versican Peptides         | Precursor m/z | Precursor z | Product ion | Product ion m/z | Retention time (min) |
|---------------------------|---------------|-------------|-------------|-----------------|----------------------|
| LATVGELQAAWR (N-terminal) | 657.8619      | 2           | y6          | 744.42          | 155.1                |
|                           |               |             | y7          | 873.46          |                      |
|                           |               |             | y8          | 930.48          |                      |
|                           |               |             | y9          | 1029.55         |                      |
|                           |               |             | y10         | 1130.60         |                      |
|                           |               |             | y11         | 1201.63         |                      |
| YEINSLIR (C-terminal)     | 504.2796      | 2           | y3          | 401.29          | 118.1                |
|                           |               |             | y4          | 488.32          |                      |
|                           |               |             | y5          | 602.36          |                      |
|                           |               |             | y6          | 715.45          |                      |
|                           |               |             | y7          | 844.49          |                      |

## Supplemental Figure I




**Supplemental Figure I.** Experimental design. Hypertension was induced by treating 10-week-old Adamts5<sup>+/+</sup> and Adamts5<sup>Δcat</sup> mice with AngII for 4 weeks. An ultrasound was performed before and after 4 weeks of AngII infusion. Blood pressure measurements were acquired at 3 time points: 2 days before and 5 and 27 days after osmotic mini-pumps for AngII infusion were implanted.

## Supplemental Figure II



**Supplemental Figure II.** Quantification of versican (CSPG2) and TGF-β in the aortas of AngII-treated Adamts5<sup>+/+</sup> and Adamts5<sup>Δcat</sup> mice by densitometry. Bars represent mean ± SD. Statistical significance was calculated using unpaired Student's *t*-test. \* denotes P < 0.05


## Supplemental Figure III



**Supplemental Figure III. Gene expression in murine aortas.** Relative gene expression of *Adamts1*, *4* and *5*, *Tgfb1*, *2* and *3* and *Tgfbr1*, *2* and *3* in aortas from untreated Adamts5<sup>+/+</sup> (n=6) and Adamts5<sup>Δcat</sup> (n=5) mice. β-actin was used as reference gene. Data points are means±SD. Black squares denote *P*<0.05 as determined by Mann-Whitney tests.




## Supplemental Figure IV



**Supplemental Figure IV. LRP1 in mouse aortas.** Quantification of LRP1 in aortas of untreated and AngII-treated Adamts5<sup>+/+</sup> and Adamts5<sup>Δcat</sup> mice by densitometry. Bars represent means ± SD. The intensity values in Adamts5<sup>+/+</sup> aortas served as reference. Statistical significance was calculated using unpaired Student's *t*-test. \*\* denotes P < 0.01.

## Supplemental Figure V



**Supplemental Figure V. LRP1 siRNA, protein expression.** Quantification of LRP1, the N-terminal fragment of versican (versikine) and the two forms of ADAMTS1 by densitometry. SMCs transfected with scrambled siRNA served as reference. Bars represent mean ± SD. Statistical significance was calculated using one-way ANOVA with Dunnett's *post hoc* test. \* denotes P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001.